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ABSTRACT 
 Cancer is a collection of diseases with many different manifestations and is the second 
leading cause of death in the United States.  Breast cancer accounts for nearly one third of 
cancer diagnosis in women.  Prolactin (PRL) functions as a lactogen and as a mammary gland 
differentiation factor.  PRL acts in an autocrine/paracrine manner within the mammary gland and 
in breast tumors which implies PRL may be involved in breast cancer progression.  This is 
corroborated by the PRLR over-expression in breast cancer cells lines and the majority of patient 
biopsies.  These reasons make PRL and PRLR attractive targets for breast cancer treatment and 
prevention. 
Transgenic mice expressing hPRL or G129R, under the regulation of the metallothionein 
(Mt) promoter, were fed a chemical carcinogen, 9,10-Dimethyl-1,2-benzanthracene (DMBA).  
G129R transgenic mice exhibited decreased growth rate of chemically-induced tumors, while 
hPRL transgenic mice had an increased cancer rate.  Microarray analysis revealed that hPRL 
transgenic mammary gland showed an expression pattern similar to those of a pregnant mouse, 
while the G129R transgenic gland revealed an increase in various apoptotic markers. 
Previously, fusion proteins composed of a PRLR antagonist (G129R) and anti-tumor 
domains were developed; these included fusions with an angiogenesis inhibitor (Endostatin), an 
immune system modulator (interleukin-2), and a cytotoxin (PE38KDEL).  The rationale was that 
each fusion protein would target the mammary gland via the G129R moiety and attack different 
hallmarks common to tumor cells via the second moiety.  A novel clinically-relevant model was 
generated by surgically removing spontaneous mammary tumors from MMTV-neu transgenic 
mice and monitoring tumor recurrence while treating with the fusion protein cocktail.  Tumor 
recurrence was significantly delayed in groups treated with the fusion proteins in comparison to 
the control group.  In conclusion, targeting multiple hallmarks of cancer using a combination of 
dual function therapeutics was highly effective in the aggressive MMTV-neu mouse tumor model. 
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 CHAPTER ONE 
INTRODUCTION 
1.1 Cancer 
Cancer is the second leading cause of death within the United States, surpassed only by 
heart disease (Society 2007).  Over the past three decades, while heart disease mortality rates 
have been in steady decline, there has been little improvement in the mortality rates of cancer 
patients over this same time period.  However, this should not be interpreted as a lack of 
understanding or advancement in the overall nature of the disease. 
Cancer is a myriad collection of diseases in which abnormal cells divide without control.  
This uncontrolled growth can lead to two classes of tumors, benign or malignant.  A benign tumor 
is a collection of these cells that have lost the ability to naturally control their division and death, 
and are usually well incased within the tissue of origin.  These tumors are rarely life-threatening, 
can be surgically removed and usually do not grow back.  Malignant tumors are generally more 
serious and have the potential to develop into life-threatening disease.  In many cases the cells 
from these tumors are able to evade the body’s natural defense mechanisms and move 
throughout the body in the circulatory and lymphatic vessels to invade other tissues 
(metastasize). 
 Cancers are generally named for the tissue or origin, but can usually be placed into one 
of four different categories (Hodges and Rowlatt 1994).  The first of which is termed carcinoma.  
These are cancers generally derived from epithelial cells or cells of ectodermal origin of the skin 
or tissues that line or cover the internal organs.  Carcinomas include skin cancers, many cancers 
of the mammary gland, and lung cancers.  Sacromas are of mesenchymal origins and include 
cancers of the bone, cartilage, blood vessels, and other connective and supportive tissues.  
Lymphomas or myeloma are cancer of cells of bone marrow origin with leukemia being a 
common manifestation.  Finally, central nervous system cancers are malignant tumors of the 
brain and spinal cord. 
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 Approximately 1.5 million people are expected to be diagnosed with cancer in 2007, a 
figure which has increased by approximately 200,000 over the previous year (Society 2007).  The 
steady increase of this number over the past decade is generally attributed to an increase in the 
sensitivity of detection methods and a push for earlier screening of patients, rather than a losing 
effort in the battle against the disease.  The observation that cancer deaths have been steadily 
decreasing over the past decade (with the exception of 2006, which had a slight increase) and 
the increase in the percentages of the 5 and 10 year survival rate is a positive indication that our 
understanding of the disease is yielding potent treatment methods.  However, there is still a great 
deal to learn. 
1.2 Hallmarks of Cancer 
 Carcinogenesis is the process by which cancers are generated.  It is a multi-step 
mechanism resulting from the accumulation of errors (altered DNA bases or mutations) in vital 
regulatory pathways. The tumor is generated by the amplification of a single cell (clonal origin) 
which then multiplies and acquires additional changes that give it a survival advantage over its 
neighbors (Huang, Ng et al. 1997). There are more than 100 distinct types of cancer, as well as 
subtypes of malignancies that have been described.  However, there have been several common 
traits identified within all cancers.  These traits were termed “Hallmarks of Cancer” by Hanahan 
and Weinberg in 2000, as shown in Figure 1.1. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Energetic requirements 
for tumor
Immune system 
evasion
Stem cell source 
of tumor
 
 
 
Figure 1.1.  Hallmarks of Cancer (Hanahan and Weinberg 2000).  Hanahan and Weinburg 
postulated that most if not all cancers have acquired the same set of functional capabilities during 
their development, albeit through various mechanistic strategies.  The hallmarks of stem cell 
source, energetic requirements, and immune system evasion have been added to the original six 
hallmarks since publication of this landmark paper in 2000. 
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  The first clearly established hallmark is self sufficiency in growth signaling.  Normal cells 
require mitogenic growth signals before moving into an active proliferative state. Transmembrane 
receptors that bind to diffusible growth factors, extracellular matrix components, and cell adhesion 
molecules are utilized to transmit this signal into the cell.  The cells acquire the ability to 
circumvent the mitogenic growth signals in one or any combination of three strategies.  First, 
tumors cells have been shown to produce their own mitogenic ligands, as is the case in 
glioblastomas and squamous cell metaplasia and carcinomas of the bladder which acquire the 
capability to produce PDGF and TGFα (Betsholtz, Nister et al. 1989; Tungekar and Linehan 
1998).  Second, many cancers have modification to or over-expression of their extracellular 
receptors, which enable the cells to become hyper-responsive to the growth factors.  A classic 
example of this found in breast cancer where HER2 is found to be over-expressed in 20-30% of 
patients (Ciardiello and Tortora 2001; Miles 2001).  Lastly, the intracellular signaling molecule 
associated with these receptors can be altered to the point where signaling is constitutely 
activated. Such is the case in approximately 25% of cancer where Ras is structurally modified to 
elicit growth signaling without stimulation by the normal upstream regulators (Medema and Bos 
1993). 
 The second hallmark of cancer is insensitivity to anti-growth signaling.  Homeostasis is 
maintained within the cell by an elaborate complex of inhibitors either embedded in the 
extracellular matrix of the cell or neighboring cells as well as soluble proteins.  The anti-growth 
signal, like their proliferative counterparts, is received by surface receptors which are coupled to 
intracellular signaling molecules.  Tumors evade these processes by a reversible or irreversible 
mechanism.  Disruption of the pRb pathway can be used as a classic example of both processes.  
In many cancers the TGFβ receptors, which govern the pRb signaling circuit, can be mutated 
(Reiss, Vellucci et al. 1993) or display a dysfunction receptor (Markowitz, Wang et al. 1995). 
 Deregulation of programmed cell death, apoptosis, is displayed in virtually all cancer to 
some extent.  Once apoptosis has been triggered, a precisely choreographed series of steps is 
initiated in which membranes are disrupted, cytosolic and nuclear skeletons are broken down, 
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 DNA becomes fragmented, and the shriveled cells are engulfed by nearby phagocytic cells within 
24 hours.  The loss of the ability of the cell to enter the process represents the third hallmark of 
cancer.  The evasion can occur by the alteration of sensors (IL3 (Evan and Littlewood 1998)) of 
the effectors (loss of pTEN tumor suppressor (Cantley and Neel 1999)) of the apoptotic 
machinery. 
 Disruption of any of the first three hallmarks does not ensure expansive tumor growth.  It 
has been demonstrated quite extensively that cells in culture have a finite replicative potential 
(Hayflick 1997).  The number of replications is dictated by the length of the telomere, the several 
thousand repeat of a 6 base pair sequence, which is shortened each time the DNA is copied 
every cell cycle.  The maintenance of the telomere is evident in all types of cancer (Shay and 
Bacchetti 1997).  In 85-90% of the malignant growths, the up-regulation of telomerase, the 
enzyme which adds hexanucleotide repeats to the ends of telomeric DNA (Bryan and Cech 
1999), has been up-regulated (Harley and Kim 1996).  It is the acquisition of this limitless 
replicative potential that constitutes the forth hallmark of cancer. 
 Cells within any tissue must reside within 100 µm of a capillary blood vessel to maintain 
an adequate oxygen and nutrient supply.  The tumor’s ability to overwhelm the tightly controlled 
process of growing blood vessels, angiogenesis, is the fifth hallmark of cancer.  Cancers appear 
to trigger the angiogenic switch by changing the balance of angiogenesis inducers and offset 
inhibitors (Hanahan and Folkman 1996).   
The sixth hallmark of cancer proposed by Hanahan and Weinberg is the primary tumor’s 
capability to invade adjacent tissue and spread itself to distant sites.  This process involves a 
series of complex interactions between the tumor cell and the extracellular environments it 
encounters from primary tumor site to the distant secondary tumor formation.  The function of 
cellular adhesion molecules, such as E-cadherin, has been lost in many epithelial cancers 
(Christofori and Semb 1999).  Normally, E-cadherin would suppress the invasion of epithelial 
cells.  The functional elimination of E-cadherin represents a major achievement in the cell’s ability 
to invade and metastasize.  Research is also ongoing to determine how this process becomes 
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 uncoupled.  Initially, epithelial cells lose their polarity upon transformation to a cancerous state.  
Examples of dysfunctions in cancer cells would be the loss of functional PAR3 and PAR6 (Katoh 
2005), which are involved in RAC GTPase regulation and PKC signaling respectively.  Both are 
families of proteins that are involved in many functions, including remodeling of the cytoskeleton, 
modulation of ion channels, specifically E-cadherin, and cell proliferation. 
Since the publication of Hanahan and Weinberg’s paper in 2000, there have been 3 
hallmarks generally accepted as additions to their list.  The seventh hallmark is one very old 
observation within cancer biology, that is the altered metabolism of tumors cells, first postulated 
by Warburg in 1956 (Warburg 1956).  The hypoxic and highly acidic environment requires the 
cells to switch to anaerobic glycolysis which requires higher levels of glucose.  This switch leads 
to alterations in the gene expression profiles of the genes involved in metabolism.  The profile 
differences include high glucose transport, reduced fatty acid oxidation, and modified amino acid 
metabolism (Claudino, Quattrone et al. 2007).  The mitochondria, which play an important role in 
oxidative metabolism, have also been demonstrated to be involved in the altered metabolism, and 
have been shown to have notable differences in the genetic and biochemical levels when 
comparing normal and cancerous cells (Zanssen and Schon 2005). 
Neoplastic cells develop various strategies to escape immune surveillance.  This 
represents the eighth hallmark of cancer.   Cancerous cells weakly express the major 
histocompatibility complex molecules, thus hindering the recognition of the neoplastic cells by T 
lymphocytes. Defective expression by the tumor of the ligands for the T cell activation co-
stimulatory molecules is particularly harmful for the immune response since it induces tolerance. 
Finally, tumor cells can inactivate effector T lymphocytes through the secretion of inhibitory 
cytokines, induction of apoptosis or functional inactivation (Costello, Gastaut et al. 1999). 
Finally, evidence that certain cells within the tumor are the only cells that acquire the 
ability to initiate new tumors is the ninth hallmark of cancer.  These rare, but vital, cells have been 
termed cancer stem cells.  They possess striking similarities with normal stem cells:  tumors may 
often originate from the transformation of normal stem cells, similar signaling pathways may 
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 regulate self-renewal in stem cells and cancer cells, and cancer cells may include rare cells with 
indefinite potential for self-renewal that drive tumorigenesis (Myers 1975). 
1.3 Chemotherapy 
Conventional chemotherapy has employed small molecules that target DNA synthesis 
and replication activities (i.e. alkylating agents, anti-metabolites, plant alkloids, topoisomerase 
inhibitors, etc.) to rapidly kill dividing cancer cells along with many others, thereby creating a large 
number of side effects.  These agents by themselves or in addition to radiation therapy are 
usually the first step in treating cancer.  Treatment is followed by surgical removal of the shrunken 
mass, which is followed by further rounds of radiation and chemotherapy.  While there have been 
vast improvements in the equipment for delivering radiation therapy (Romanelli, Schaal et al. 
2006) and new methods of administering the chemotherapy (Kim 2007), these agents often 
damage many of cells, thereby creating significant side effects.  The use of these agents in 
combination in order to reduce the dose needed and improve the therapeutic outcome, 
represents the current trend, but still focuses on one aspect of cancer cell physiology, DNA 
replication. 
Cancer chemotherapy has made a shift in the past 10 years, with a move toward 
specifically targeting cancer cells.  A target is usually a single gene, gene product, or signaling 
pathway that has been identified on the basis of genetic analysis or biological observations 
(Wang, Qi et al. 2002; Lindsay 2003).  These signaling pathways rely heavily on protein kinases 
and their over-expressed receptors that have lost control of their regulation in cancer cells 
(Manning, Whyte et al. 2002).  Small molecules, peptides, protein antagonists, and antibodies 
have been developed to target cancer cells at the signaling pathway level.  These agents can 
affect the signaling pathway by modulating the ligand concentration of the over-expressed 
receptor, blocking the receptor-ligand association, or modulating the signaling at the intercellular 
portion of the receptor itself or downstream signaling molecules.  These agents represent a 
broadening of the attack on the physiological needs of the cancer cell and a decrease in the side 
effects associated with treatment.  
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 1.3.1 Targeted Therapy 
1.3.1.1 Modulating Ligand Concentration 
 Receptor activity can also be modulated by ligand synthesis and concentration.  Drugs 
which interact with the metabolic pathways involved in ligand synthesis decrease the amount of 
ligand available to bind with receptor and elicit signal transduction.  Aromatase inhibitors, which 
block the non-ovarian synthesis of estrogen by inhibiting the cytochrome P450 enzyme 
aromatase, are classic examples of this mode of action (Morandi, Rouzier et al. 2004).  This 
enzyme catalyzes the conversion of androgens to estrogen in peripheral tissues and locally within 
tumors.  Type I aromatase inhibitors are steroidal analogues of androstenedione and bind 
irreversibly to the enzyme complex, causing inactivation until new enzyme is synthesized.  Type II 
aromatase inhibitors are non-steroidal drugs and bind reversibly to the aromatase complex.  By 
inhibiting aromatase, the levels of estrogens are reduced by greater than 97 percent in 
postmenopausal women (Brodie 2003).  Recent studies have shown aromatase inhibitors to be at 
least as effective in the treatment of breast cancer as Tamoxifen and have decreased recurrence 
and drug resistance issues (Morandi, Rouzier et al. 2004).  However, longer follow-up will allow 
further evaluation of long-term clinical effect. 
Insulin-like growth factor binding proteins (IGFBP’s) are naturally produced proteins 
which are present in human serum to bind IGF and keep it from binding its receptors.  
Microarrays of the breast cancer cell lines MCF-7 and MCF-10 cells treated with apoptosis 
inducing compounds, such as curcmumin, have revealed an increased expression of IGFBP’s 
(Ramachandran, Rodriguez et al. 2005).  IGFBP’s induction is not just an afterthought to 
apoptosis induction.  Treatment of prostate cancer cell lines with IGFBP-3 is enough to induce 
apoptosis by itself. 
The use of agonists or antagonists of luteinizing hormone releasing hormone (LHRH), 
also called gonadotropin hormone releasing hormone, is an established therapy for hormone-
dependent metastatic premenopausal breast cancer (Emons and Schally 1994).  Their 
mechanism of action is the suppression of ovarian oestrogen and androgen production.  
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 Convincing evidence has been accumulated that shows LHRH agonist have a direct effect on the 
proliferation of breast cancer cell lines in vitro (Grundker, Gunthert et al. 2002).  These drugs 
come in the form of small molecules, triptorelin, and peptides, cetrorelix (Grundker, Volker et al. 
2000) and are currently under investigation for the treatment of endocrine related cancer, such as 
breast, ovary, endometrial, and pancreatic cancers. 
The sequestering of ligand has been used in the case of the angiogenic growth factor, 
VEGF.  Bevacizumab, a monoclonal antibody for VEGF, accomplishes this goal by binding to the 
ligand (Muhsin, Graham et al. 2004) to the VEGFR and thereby sequesting the ligand from the 
receptor.  In vivo and in vitro tests have shown the efficacy of bevacizumab and have shown up 
to a 40% response in phase II clinical studies in colon cancer.  These promising results led to 
investigation in other cancers and it has been demonstrated effective in small cell lung cancer 
and breast cancer.  Infliximab, which is utilized in both cancer and metabolic disorders, is specific 
for TNF and prevents the signaling of cell surface receptor for TNF (Bickston, Lichtenstein et al. 
1999).  While this method can obviously have an effect on circulating ligand concentrations, 
ligands produced locally would be minimally effected by this method. 
1.3.1.2 Attacking Over-Expressed Receptors 
Another method for targeting cancer cells is to target the receptor directly.  This is 
accomplished with a wide array of small molecules, proteins antagonists, and antibodies.  
Tamoxifen is a classic example.  Tamoxifen is an estrogen analog, which is able to competitively 
bind to the estrogen receptor and inhibit further action of the receptor (Jordan 1976).  Clinically, 
Tamoxifen is the gold standard for treating estrogen receptor positive breast cancer.  However, 
data from clinical trials has returned mixed results and Tamoxifen’s benefits as a preventative 
agent is yet to be determined.  While data in BRCA heterozygous individuals has been unable to 
prove Tamoxifen’s benefits (Robson 2002), data from the NSABP P-1 study have shown a 
dramatic decrease in the number of ER-positive breast cancers in patients given Tamoxifen as a 
chemopreventative agent (Alberg, Lam et al. 1999; Wickerham 2002).  Yet another group has 
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 shown that Tamoxifen at low doses alters the IGF-1/IGFBP-3 ratio within patients and showed 
this to be detrimental to the drug’s effectiveness (Bonanni, Johansson et al. 2001). 
The HER-2 gene is a proto-oncogene observed to be over-expressed in 20-30% of 
women with breast cancer (Slamon, Godolphin et al. 1989).  Over-expression of Her2 has been 
demonstrated to cause increased DNA synthesis, cell growth rate, tumorigenicity, and metastatic 
potential (Benz, Scott et al. 1992; Chazin, Kaleko et al. 1992).  Trastuzumab (Herceptin) is a 
highly purified recombinant DNA-derived humanized monoclonal antibody that binds with high 
affinity and specificity to the extracellular domain of the HER-2 receptor (Goldenberg 1999). 
Approximately 20 antibodies are currently being evaluated in clinical trials, 10 have 
advanced to Phase II trials or further (Groner, Hartmann et al. 2004).  Many are targeted against 
the EGF receptor family in a variety of cancer sites.  Cetuximab, which competitively binds to the 
EGFR, is being studied in small cell lung cancer.  Panituzumab, which interferes with HER-2 
dimerization, is being studied for use in cancer patients with elevated HER-2 levels, much the 
same as Herceptin.  
 Protein antagonist treatments are not quite as evolved as small molecules and antibody 
therapies.  There are two basic premises under which protein therapies fall.  First, increasing the 
concentration of native binding proteins which sequester ligand from receptor is a natural way in 
which the body maintains growth signals, discussed above with IGFBP3.  Secondly, those which 
bind to the receptor and block the native protein from interacting with the receptor, without 
eliciting signal transduction (human prolactin antagonist, G129R). 
There is considerable evidence to the involvement of prolactin in the reduction of breast 
cancer.  The mutation that replaces the Gyl amino acid at position 129 of the prolactin molecule 
with an Agr (G129R) (Chen, Ramamoorthy et al. 1999) has proven to be a useful agent in the 
fight against breast cancer.  The mutant protein has been demonstrated to induce apoptosis or 
programmed cell death.  The induction was observed through one of the hallmark apoptotic 
markers of internucleosomal DNA cleavage.  G129R has been shown to slow the growth of 
breast cancer cell xenografts in mouse models.  Investigation into the mechanism of apoptosis 
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 induction revealed that G129R inhibits the phosphorylation of Stat3 (Cataldo, Chen et al. 2000).  
Beck et al. (Beck, Peirce et al. 2002) examined the expression of bcl-2 in relation to prolactin and 
hPRL-G129R levels.  Bcl-2 is a human proto-oncogene that when over-expressed, will ultimately 
lead to inhibition of cell death (Korsmeyer 1999).   The prolactin molecule was shown to play a 
role in the regulation if the bcl-2 gene.  Prolactin increased expression, while the hPRL-G129G 
decreased expression (Beck, Peirce et al. 2002). 
1.3.1.3 Modulation of Receptor Signaling 
 The final method of targeting cancer cells is modulation of the signaling at the 
intracellular portion of the receptor itself or downstream signaling molecules.  This method has 
produced a wide array of molecules and targets, ranging from receptor tyrosine kinase inhibitors, 
such as EGFR and VEGFR, to inhibitors of src, c-kit, pik, AKT, MAPK.  The majority of these 
agents are small molecules.  The most popular target is the receptor itself, competitively or 
irreversibly binding to the intracellular portions of the receptor responsible for signal transduction. 
Both Iressa and Erlotinib are selective ErbB1 tyrosine kinase inhibitors.  They have been 
shown to also bind to HER-2, but with 200 fold less affinity than ErbB1 (Thomas and Grandis 
2004).  They prevent the autophosphorylation of the receptor (Arteaga and Johnson 2001; 
Bartsch, Wenzel et al. 2007).  While the specific mechanism of anti-tumor activity is not clear, it is 
speculated that treatment leads to G1 cell-cycle arrest through inhibited CDK activity (Moyer, 
Barbacci et al. 1997; Arteaga and Johnson 2001).  Both drugs have shown limited success in 
clinical trials, with only 10 to 15% of patients responding to the drugs (Fukuoka, Yano et al. 2003; 
Perez-Soler, Chachoua et al. 2004).  Further classification of tumors within the Iressa study have 
led to very interesting results.  Patients presenting at least one point of mutation around the ATP-
binding pocket of the tyrosine kinase domain of the EGFR were shown to have a response rate of 
greater than 80% (Dancey and Freidlin 2003; Lynch, Bell et al. 2004).  Therefore, further 
screening of patient’s tumors before treatment may lead to more effective uses of 
chemotherapies. 
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  The recruitment of blood vessels to the tumor as a source of oxygen and nutrients is also 
a common target for small molecule drug development.  The most common target is VEGF 
receptor.  Drugs like Vatalanib, Sutent, and Sorafenib have been shown to inhibit vascular 
formation by varying methods (Arora and Scholar 2005).  There is limited data as to their direct 
mechanism of action at this point.  Vatalanib is a more potent inhibitor of VEGFR-2, but does 
inhibit VEGFR-1 (Lin, Podar et al. 2002).  Sutent has been shown to be a much more broad 
range tyrosine kinase inhibitor, affecting PDGF and c-KIT as well as VEGF (Mendel, Laird et al. 
2003).  However, in clinical studies it has been shown to be more effective in its antiangiogenenic 
activity and tumor regression capabilities when compared to Vatalanib, 33 versus 5%, 
respectively (Eskens 2004; Rini and Small 2005).  While Sorafenib was originally developed as a 
Raf kinase inhibitor, it was subsequently found to inhibit many tyrosine kinase activities on 
VEGFR, EGFR, and PDGFR (Wilhelm, Carter et al. 2004; Strumberg, Richly et al. 2005) and has 
significant anti-tumor activity in renal, colon, pancreatic, lung, and ovarian cancers. 
 The proteasome is a multi-catalytic complex that serves to eliminate misfolded and 
damaged proteins as well as protein regulated throughout the cell cycle.  Protein deregulation via 
the proteasome pathway is critical to regulation of such processes as cell cycle progression and 
apoptosis.  Inhibition of the proteasome results in disruption of protein homeostasis and leads to 
adverse effects on cell signaling cascades.  Bortezomib, a dipeptidyl boronic acid, functions as a 
specific and selective reversible inhibitor of the 26S proteasome (Ling, Liebes et al. 2003; Yang, 
Ikezoe et al. 2004).  Initial phase I studies have shown modest efficacy as a single agent therapy, 
with a response rate of 8% and a 21% stable disease rate (Fanucchi, Fossella et al. 2006). 
1.3.1.4 Utilizing Targeted Therapies as Delivery Mechanisms 
Finally, receptors can be utilized as a delivery mechanism.  Fusion proteins possessing a 
domain which can be recognized by the active site of the receptor and a second domain that 
targets one of the hallmarks of cancers are under development (van Ojik and Valerius 2001; 
Langenheim and Chen 2005).  These molecules possess the power of specificity, targeting the 
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 receptors that are over-expressed in cancer cells, and the potency of a cytotoxin, or immune 
system modulator. 
Agents targeted to the over-expressed receptors of cancer cells have also been utilized 
as delivery molecules, by developing multi-functional fusions of both antibodies and protein 
antagonists.  Recently, modulation of Fc portion of the antibody to interact with the Fc receptors 
of NK and myeloid cells have been investigated to trigger cytotoxic molecule secretion and 
phagocytosis (Deo, Graziano et al. 1997).  Several antibody-toxin fusion proteins have been 
developed.  These molecules are generated by genetically fusing a single chain variable fragment 
specific to a receptor to a truncated version of a toxin.  One such examples is an EGFR specific 
antibody fused to Pseudomonas exotoxin A (Bruell, Bruns et al. 2005).  This protein has shown 
specific binding and toxicity against EGFR-positive, metastatic pancreatic carcinoma cells both in 
vitro and in vivo.  Secondly, the VEGF121/rGEL fusion, which contains a VEGF specific 
recognition domain and the recombinant plant toxin gelonin, has been shown to be highly specific 
to cells expressing the KDR receptor and inhibit tumor growth in a highly metastatic human 
bladder carcinoma cell line in an orthotopic model in nude mice (Mohamedali, Kedar et al. 2005). 
 Protein antagonist therapy has its limitations, which is normally the serum half-life of the 
protein within the body.  To decrease this limitation, chemical modification of the protein by 
adding long hydrocarbon chains have shown some promise.  Studies of a lysine-deficient mutant 
of TGF-α (mTNF-K90R) that has been site specifically mono-PEGylated at the amino terminus, 
has shown that in vitro binding of the TNF receptor is increased in the altered protein as well as 
demonstrated a significant increase in the serum half-life (Shibata, Yoshioka et al. 2004). 
Unpublished data within our own laboratory have also shown that hexylation of G129R also 
dramatically increases the serum half-life, as well as decreases the activation of Stat5 within the 
liver to levels greater than unmodified G129R. 
 The creation of fusion proteins has the effect of increasing the serum half-life and also 
resulting in multifunctional proteins.  As is the case with the G129R fusion proteins generated by 
this laboratory.  Fusions of immuno-regulatory proteins, vascular formation inhibitors and bacterial 
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 toxins (Zhang, Li et al. 2002; Beck, Chen et al. 2003; Langenheim and Chen 2005) have 
demonstrated increasing serum half-life for the prolactin antagonist while retaining ability to 
competitively inhibit the activation of Stat5, a hallmark of prolactin activity.  These fusion proteins 
have also been shown in vitro to retain the functionality of the second moiety, while showing an 
increased ability in vivo to slow the tumor growth of a prolactin receptor positive cell line when 
compared to higher doses of G129R by itself.  LHRH has been utilized as the targeting moiety in 
a large number of fusion proteins, which include bacterial toxins (PE40) and human proapoptic 
proteins (Bik, Bax, Bak) (Azar and Lorberboum-Galski 2000; Ben-Yehudah and Lorberboum-
Galski 2004; Li, Sun et al. 2006). 
1.3.2 Combination Therapy 
1.3.2.1 Using the Old with the New 
Initial studies of new targeted therapies performed in combination with traditional 
radiation and chemotherapeutic agents with the targeted agent show an ability to sensitize the 
cancer cell to the traditional treatments.  In vitro and in vivo preclinical studies showed that 
administration of Herceptin alone or in combination with paclitaxel or carboplatin was able to 
significantly inhibit the growth of breast tumor derived cell lines that over-express the HER-2 gene 
product.  In the latest studies of Herceptin (Piccart-Gebhart, Procter et al. 2005; Romond, Perez 
et al. 2005), the drug was associated with substantial reductions in disease recurrence among 
women with HER2-positive breast cancer.  The patients had the tumors surgically removed and 
were given the traditional regimen of chemotherapeutic drugs before and after surgery.  They 
were then given Herceptin for one year.  At the one year mark, Herceptin was responsible for a 
significant decrease in the recurrence and death rates with very limited incidence of the 
cardiotoxicity demonstrated in more terminal patients previously studied.  Similar results have 
been shown with bevacizumab (Muhsin, Graham et al. 2004), EGFR inhibitors (Gandara, Davies 
et al. 2007), SERMs (Sachelarie, Grossbard et al. 2006), Bortezomib (Davies, Lara et al. 2007), 
LHRH antagonists (Emons, Grundker et al. 2003), etc. 
 
 14
 1.3.2.2 Targeting the Same Oncogene 
Combination strategies are evolving to utilize both traditional and targeted therapies to 
fight cancer.  These strategies are based on at least three distinct principles.  The first strategy is 
targeting the same oncogene with multiple drugs.  Several therapies have been developed to 
target the Her2 receptor; the combination of herceptin and lapatinib, the small molecule inhibitor 
of Her2, is currently under investigation (Geyer, Forster et al. 2006).  Results have demonstrated 
that lapatinib plus capecitabine, a 5FU prodrug, was superior to any combination tested.  
However, there were only a limited number of patients given the herceptin, lapatinib combination 
in this study.  Herceptin given in combination with pertuzumab, the monoclonal antibody that 
prevents Her2 dimerization, synergistically inhibited the survival of HER-2 over-expressing BT-
474 cells (Nahta, Hung et al. 2004). The clinical evaluation of this combination is currently under 
investigation (Walshe, Denduluri et al. 2006).   
There are many combination options being utilized that target the EGFR family of 
receptors.  The combination of the two antibodies directed toward HER-2 has shown great 
promise in preclinical studies.  Cetuximab has been utilized in combination with various small 
molecule tyrosine kinase inhibitors, gefitinib or erlotinib, in mouse xenograft studies and shown 
significant reduction in proliferative markers (Huang, Armstrong et al. 2004; Matar, Rojo et al. 
2004).  The use of erlotinib and pertuzumab has been shown to be advantageous as a 
combination in both non-small cell lung cancer and breast cancer xenografts (Friess, Scheuer et 
al. 2005).  The tyrosine kinase inhibitors have also been tried in combination (Harari 2004).  The 
treatment of SU111925, a small molecule inhibitor of Her2, and gefitinib has shown to decrease 
EGFR phosphorylation of A431 cells in vitro and in vivo (Christensen, Schreck et al. 2001).  While 
each individual agent decreased the xenograft growth of these cells, no data was reported on 
their effects in combination.   
Utilizing SERMs in combination with aromatase inhibitor would be another example of 
targeting the same oncogene with multiple drugs.  These combinations have shown that timing of 
administration can be an important factor in determining success in that the combination therapy 
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 works better when administered sequentially rather then in direct simultaneous combination 
(Poole and Paridaens 2007).  Most studies nearing their 5 or 10 year report times have dealt with 
the administration of SERMs, estrogen agonists, or aromatase inhibitors given in succession.  For 
example, the ATAC study (Arimidex, Tamoxifen, Alone or in Combination) has shown that 
administration of Arimidex, a third generation aromatase inhibitor, is more effective than 
Tamoxifen alone.  The study also showed that switching to Arimidex is at least as effective as 
continuing Tamoxifen in remaining disease free without observing the negative side effects of 
Tamoxifen (Aapro and Forbes 2003).  Preclinical studies are investigating the benefits of creating 
a therapeutic estrogen blocking antiestorgens in combination with aromatase inhibitors.  The 
combination of toremifene (an antiestrogen) and atamestane (an aromatase inhibitor) was 
superior to either agent alone in in vitro and in vivo studies utilizing Ac-1 cells and xenograft of 
those cells in nude mice (Sabnis, Macedo et al. 2007). 
1.3.2.3 Hitting the Oncogene Along Its Signaling Cascade 
The second combination strategy being employed is attaching targeting multiple targets 
along the same oncogenic signaling cascade.  Using Her2 signaling as an example, after Her2 is 
activated it triggers signaling molecules including but not limited to Ras/Raf/MAPK, JAK2/STAT, 
and PI3K/AKT (Bazley and Gullick 2005).  The use of a receptor-targeting drug in combination 
with a drug targeted to a particular intracellular component of the same receptor’s signaling 
cascade provides an example of this method.  The src homology domain has been shown to 
have a critical effect on HER-2 signaling and has been demonstrated to be an important factor for 
HER-2 over-expressing cancers to metastasize (Schade, Lam et al. 2007); therefore, the use of 
dasatinib, a small molecule inhibitor of src and abl, could prove to be beneficial when used in 
combination with herceptin (Finn, Dering et al. 2007).  Prolactin has also been shown to activate 
HER-2 receptor signaling in breast cancer (Yamauchi, Yamauchi et al. 2000; Huang, Armstrong 
et al. 2004), and the use of herceptin in combination with the PRLR antagonist, G129R, has been 
shown to have an additive inhibitory effect on HER-2 and MAPK phosphorylation and cell 
proliferation in T47D and BT-474 cells both in vitro and in vivo (Scotti, Langenheim et al. 2007).  
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 G129R has also been shown to be more effective when given in conjunction with Tamoxifen 
(Ramamoorthy, Sticca et al. 2001).  This study showed that with use of Tamoxifen, a selective 
estrogen-receptor modulator (SERM) (Brown and Lippman 2000), there was a significant 
decrease in the number of cells when treating various cancer cell lines in vitro.  Studies have 
been performed on the combination of tyrosine kinase inhibitors and MAPK inhibitor (Jimeno, 
Rubio-Viqueira et al. 2007).  Here it was shown the combination inhibited the MAPK signaling 
pathway and exerted anti-tumor effects in vitro and in vivo when tested in tumors resistant to 
either agent alone.  Most of these methods have yet to make it to clinical trials, but do show great 
promise. 
An important mediator of the PI3K-AKT pathway is mTOR, which is a member of the 
phosphoinositide-kinase-related kinase family that includes PI3K (Bjornsti and Houghton 2004).  
mTOR acts as a central sensor for nutrient or energy availability.  In the presence of mitogenic 
stimuli and sufficient nutrients, mTOR relays a positive signal to translational machinery which 
facilitates cell growth.  Several agents have been developed to target mTOR, such as rapamycin 
and its derivatives, and their potential as cancer treatments is being investigated.  Considering 
the immense amount of data demonstrating that EGFR signals through PI3K-AKT, it should not 
be surprising that mTOR can influence EGFR signaling (Zhou, Tan et al. 2004).  There is also 
accumulating evidence that PI3K-AKT also signal independently of receptor tyrosine kinases 
(Aoki, Blazek et al. 2001).  This indicates that using mTOR inhibitors in combination with EGFR 
inhibitor (herceptin, cetuximub, erlotinib, etc.) would have a profound effect on tumor cell biology.  
Using glioblastoma cell lines, it has been demonstrated that any number of combinations, but not 
single agents, of receptor tyrosine kinase inhibitors, and/or RNA interference decreased 
signaling, cell survival, and anchorage-independent growth (Doherty, Gigas et al. 2006; Stommel, 
Kimmelman et al. 2007).  It can be postulated that this strategy would be beneficial to all solid 
tumors that are refractory to existing therapies. 
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 Several levels of interaction exist between ER and EGFR.  First, estrogen treatment has 
been shown to phosphorylate EGFR and physically interact with EGFR (Matsuda, Kadowaki et al. 
1993).  Also, EGFR can activate ER via p38 MAPK, a downstream kinase of EGFR (Ali and 
Coombes 2002).  Based on this crosstalk between ER and EGFR, the combination or ER 
targeted treatment (Tamoxifen and other SERMs, or aromatase inhibitors) with any of the number 
of EGFR targeted therapies have been investigated.  In fact the combination of Tamoxifen with 
gefitinib, in vitro, even in Tamoxifen resistance cell lines has demonstrated improved anti-tumor 
effects (Gee, Harper et al. 2003).  Several combinations, such as herceptin with letrozole, 
gefitinib with fulvestrant or anastrozole, have made their way into clinical trials and their 
feasibilities are being determined (Ellis 2004).  The combination of LHRH antagonist and EGFR 
antagonist would fit into either of the first two categories.  LHRH has been shown to alter the 
concentration of circulating sex hormone, thus lowering the ligand concentrations (Emons, 
Grundker et al. 2003).  It has also been demonstrated the LHRH antagonists can decrease EGFR 
phosphorylation and subsequent expression of c-fos (Grundker, Volker et al. 2000); therefore the 
combination of LHRH antagonists with EGFR targeted therapies could prove to be a viable option 
in endocrine related cancers. 
A key intracellular role of IGFBP-3 was shown by Liu, et al. with the discovery of nuclear 
retinoid X receptor α serving as a binding partner to IGFBP-3 (Liu, Lee et al. 2000).  There they 
showed that co-transfection of IGFBP-3 with retinoid X receptor α potently and dose-dependently 
inhibited retinoic acid signaling via retinoic acid response element, but enhanced retinoid X 
receptor specific ligand signaling via the retinoid X response element.  Later this same group 
utilized inhibitor of both IGFBP-3 and retinoid X receptor ligands to show a synergistic effect on 
apoptosis induction leading to inhibition of prostate cancer growth both in vitro and in vivo (Liu, 
Lee et al. 2005). 
1.3.2.4 Targeting Multiple Hallmarks of Cancer 
Targeting multiple hallmarks of cancer by combining cancer therapeutics is under 
investigation.  The vast majority of the new targeted therapies have been shown to sensitize or 
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 improve the efficacy of more traditional chemotherapies that are focused on DNA replication.  
Herceptin has been shown to increase the response rate with decreased cardiac events over 
paclitaxel when used in combination (Dawood, Gonzalez-Angulo et al. 2007).  Similar findings 
have been demonstrated with bevacizumab and carboplatin/paclitaxel or gemcitabine/cicplatin.  
The use of Tamoxifen and aromatase inhibitors as adjuvant therapies also falls into this strategic 
category, and both of these agents are common drugs used in the treatment of breast cancer with 
traditional chemo and radiation (Carlson, Anderson et al. 2007).  The combination of cetuximab, 
targeting the growth factor sensitivity hallmark, with bevacizumab, targeting the angiogenesis 
hallmark, has been demonstrated effective in small cell lung cancer (Thatcher 2007).  There are 
also clinical trials underway which are investigating using bevacizumab in combination with 
erlotinib and cetuximab or Herceptin and lapatinib (Razelle Kurzrock 2007).  Preclinical studies 
have investigated the combination of conventional chemotherapeutic agents with inhibitors of NF-
kappaB (Fabre, Carvalho et al. 2007).  Here the inhibitor of NF-kappB itself had little to no effect 
on the outcome of the conventional chemotherapy.  However, an inhibitor of NF-kappaB-
activating I-kappaB kinase complex, BAY11-7082, or knockdowns of essential NF-kappaB 
subunits via RNA interference were shown to synergistically kill multiple cancer cell lines. 
1.4 Breast Cancer 
1.4.1 Etiology 
 Breast cancers form in the tissue of the breast, usually the ducts and lobes.  It occurs in 
both men and women, although cases in women far outnumber those in men.  It is estimated that 
some 180,000 new cases will be diagnosed in 2007 and approximately 41,000 deaths will be due 
to breast cancer (Society 2007).  Ethnicity, family and personal history, and diet have been shown 
to significantly alter the incidence of breast cancer, which reflects the difference in cancer causes.  
Over the past 2 decades the mortality rate has significantly decreased, which has been attributed 
to early diagnosis and continuing improvements in breast cancer therapies.  Despite extensive 
historical and current investigation, only about 55% of breast cancer cases can be explained by 
currently identified risk factors (Bruzzi, Green et al. 1985) and thus continued investigation of the 
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 disease is needed to further understand the disease and continue to develop new preventative 
and therapeutic treatments. 
There is a plethora of epidemiological observations that have been determined to be risk 
factors associated with breast cancer (Kelsey 1993; Medina 2005).  The chance of getting breast 
cancer goes up as a woman gets older, most cases occurring post-menopause in women over 
60.  Reproductive and menstrual history plays a key role in breast cancer development.  Factors 
that have been shown to increase a women’s risk over developing breast cancer include the age 
she has her first child, age of first period, age of menopause, never having children, and use of 
hormone replacement therapy.  A personal or family history increases the likelihood of acquiring 
the disease, especially if the age of onset is before 40.  Race plays a significant role, as 
Caucasian women are more frequently diagnosed than Latin, Asian, or African American women.  
There are also links to dietary and physical activity levels that have shown increased risk. 
This evidence, along with corroborating experimental data indicate the risk of developing 
breast cancer is strongly dependent on the ovary and endocrine conditions modulated by ovarian 
function, such as menarche, late menopause, and parity (Russo, Moral et al. 2005).  Both early 
menarche and late menopause equate to prolonged exposure of the mammary gland to 
hormones like estrogen and progesterone.  These lead to the breast epithelial cells being 
stimulated to growth for greater durations.  However, the earlier a woman has a full term 
pregnancy, the less likely she develops breast cancer ((MacMahon, Cole et al. 1970; Vessey, 
McPherson et al. 1985; Lambe, Hsieh et al. 1996).  In addition, there is an abundance of 
epidemiological evidence that shows that breastfeeding elicits a protective effect on the breast 
(Perez-Escamilla and Guerrero 2004).  More recent studies have shown distinctive expression 
patterns within the mammary glands of parous women without cancer compared to those who do 
have breast cancer (Balogh, Russo et al. 2007).  These observations have led to a desire to 
better understand the molecular bias of hormone-mediated breast cancer prevention. 
During pregnancy there is a significant increase in the circulating levels of many 
hormones, such as estrogen, progesterone, prolactin, etc.  These hormones all lead to the 
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 proliferation and differentiation of the mammary gland in preparation of lactation.  Once the 
offspring has aged sufficiently, these highly differentiated cells undergo apoptosis and involute as 
a result of withdrawal of the lactogenic hormones.  It has been postulated that the full lactational 
cycle after pregnancy alters the population of cells within the mammary gland, especially the stem 
cells which are the basis for regenerating the lactating gland during subsequent pregnancies 
(Russo, Moral et al. 2005).  Rosso’s group hypothesize that the virgin gland contains cells termed 
stem cell 1, which are more susceptible to environmental insult throughout the lifespan of the 
women.  After pregnancy, breastfeeding and involution the stems cells that remain are of a 
slightly different phenotype, which is more resistance to cancer formation.  These cells are 
termed stem cell 2.  This assertion is backed by various experimental data in rodent models, 
where either experienced mother or females treated with hormone that mimic pregnancy are less 
susceptible to chemical carcinogenesis. 
1.4.2 Classification 
Breast cancer is classified in two fashions.  First, is based on the histopathology of the 
tumor and surrounding tissue (Hodges and Rowlatt 1994).  Carcinoma in situ (CIS) is a very early 
cancer that is still confined to the ducts or lobules where it started. It has not spread into 
surrounding fatty tissues in the breast or to other organs in the body. One type is lobular 
carcinoma in situ (LCIS).  This begins in the lobules, but has yet to grown through the lobule 
walls. The second is ductal carcinoma in situ (DCIS).  This is the most common type of 
noninvasive breast cancer. In DCIS, cancer cells inside the ducts do not spread through the walls 
of the ducts into the fatty tissue of the breast. DCIS is treated with surgery and sometimes 
radiation, which are usually curative. If not treated, DCIS will likely progress and become an 
invasive cancer. 
Invasive or infiltrating cancer is a term used to describe those cancers that have started 
to grow and have spread beyond the ducts or lobules. These cancers are divided into different 
types of invasive breast cancer depending on how the cancer cells look under the microscope. 
They are also grouped according to how closely they resemble normal cells in appearance. This 
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 is called the grade which helps predict whether the woman has a good or less favorable outlook. 
Invasive ductal carcinoma (IDC) starts in the milk passage, and breaks through the wall of the 
duct and spreads into the fatty tissue.  Approximately 80% of all breast cancers are IDC (Society 
2007).  Invasive lobular carcinoma (ILC) starts in the milk-producing glands.  These cancer 
spread beyond the breast to other parts of the body, just as with IDC, and represent 10-15% of 
invasive breast cancers (Society 2007).  One special type of IDC is medullary cancer and is 
characterized by well-defined boundary area between the tumor and tissue of the healthy breast, 
normally processing immune system cells at the edges of the tumor. 
Inflammatory breast cancer is a special type of breast cancer in which the cancer cells 
have spread to the lymph channels in the skin of the breast. Inflammatory breast cancer accounts 
for about 1% to 3% of all breast cancers (Society 2007). The skin of the affected breast is red, 
feels warm, and has the appearance of an orange peel. The affected breast may become larger 
or firmer, tender, or itchy. IBC is often mistaken for infection in its early stages.  Inflammatory 
breast cancer has a higher chance of spreading and a worse outlook than typical invasive ductal 
or lobular cancer. Inflammatory breast cancer is always staged as stage IIIB unless it has already 
spread to other organs at the time of diagnosis which would then make it a stage IV. 
The second fashion in which breast cancers are classified is based on the expression of 
various receptors expressed within the tumor (Hodges and Rowlatt 1994).  The presence, 
absence, or degrees of expression of the oncogene, HER-2 and hormone receptor status 
(estrogen receptor (ER) and progesterone receptor (PR) play a key role in determining the 
treatment method utilized on the patient.  Cancer cells that are either ER or PR positive typically 
stop growing when administered drugs that block these receptors or decrease circulating levels of 
these steroids.  Many drugs are available and have been reviewed previously that specifically 
target the HER-2 oncogene.   
1.4.3 Prevention 
Current advances in biomedical science have led to the identification of many such 
targets for intervention.  The progression toward invasive cancer is a multistage process involving 
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 an accumulation of mutations.  These mutations lead to increased proliferation of the affected 
tissue.  The disease can remain in a latent state for years giving rise to considerable opportunities 
for intervention.  Selective estrogen-receptor modulates have been developed to expose 
estrogen’s (SERMs) involvement in breast cancer formation.  Drugs that inhibit the formation of 
blood vessels in the tumor have been examined.  The usefulness of some very well studied 
compounds, like cyclooxygenase (COX) inhibitors, has been examined.  Finally, examination of 
tumor characteristics has led to the development of novel antagonists specific to breast cancer 
cells; such is the case with Prolactin.  
Estrogen receptors are nuclear transcription factors that are present in normal tissue of 
the breast and 60-70% of breast cancers (Brown and Lippman 2000).  SERMs are often 
nonsteroidal anti-estrogen compounds.  They competitively bind to ERs in the breast.    Drugs 
such as Tamoxifen, raloxifene, tormifene and others are classified as SERMs because they can 
have ER-agonistic, -partial-agonistic or antagonistic effects depending on the species, tissue, and 
specific ER-regulating genes.  Their molecular basis is not well known at this time, but is under 
active investigation. 
Tamoxifen, the most studied of these compounds, gained FDA approval for treatment of 
advanced breast cancer in 1977 (Brown and Lippman 2000).  Since its approval, thousands of 
women have taken the drug and many studies have been performed to re-evaluate its 
effectiveness and determine its action.  Tamoxifen has demonstrated a remarkable consistency in 
reducing breast cancer in three distinct settings.  First Tamoxifen has been demonstrated to 
reduce contralateral disease in early stage breast cancer patients by 50% (Rutqvist and 
Johansson 2007).  Second, it has been shown to reduce the risk of pre-invasive and invasive 
disease in high-risk healthy women.  Lastly, it has been conclusively shown that Tamoxifen can 
reduce the risk of invasive breast cancer in patients with DCIS (Dhingra 2001). 
Tamoxifen’s benefits do not come without risks.  There have been significantly high rates 
of endometrial cancer reported.  There have also been aggregated occurrences of vascular 
events, such as stroke and deep vein thrombosis.  Cataract development has been observed at a 
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 higher rate within the Tamoxifen taking population.  Finally, some age related quality of life 
issues, such as vaginal discharge and hot flashes, have been correlated to Tamoxifen usage 
(Cella and Fallowfield 2007). 
Raloxifene is the second most studied of the SERMs.  It was initially studied as an agent 
to reduce the effect of osteoporosis in women.  The study had a primary endpoint of reduction of 
bone fracture, but it was also noticed that there was a 76% reduction in the incidence of invasive 
breast cancer among the study group compared to the placebo group (Brown and Lippman 
2000).  Further studies are currently being evaluated on the benefit of dual Tamoxifen and 
raloxifene usage, as well as only raloxifene usage.  Currently, raloxifene does not appear to have 
the increased risk of endometrial cancer, but may share the thromboembolic events that 
Tamoxifen has shown (Swaby, Sharma et al. 2007). 
Numerous experimental and clinical studies suggest that nonsteroidal anti-inflammatory 
drugs (NSAIDs), particularly those highly selective inhibitors of COX-2 have promise as 
anticancer agents.  The COX enzyme system is composed of two distinct isoenzymes, COX-1 
and COX-2, which are known to be present in colon tumors of humans and rodents and catalyze 
the conversion of arachidonic acid to prostaglandins (Eberhart and Dubois 1995).  COX-2 
expression is induced in many tissues during inflammation, wound healing, and neoplasia and 
epithelial cell cells that over-express the enzyme develop adhesion properties and resist 
undergoing apoptosis (Tsujii and DuBois 1995).  A great deal of data has been collected 
correlating COX-2 protein expression in malignant tissue and increasingly sinister attributes of the 
tumor.  Animal models have shown that COX inhibitors can decrease the incidence and 
multiplicity of experimentally induced breast cancer.  It has also been shown that treatment of 
established tumors with COX inhibitors can reduce the tumor volume over time.  Potentially, COX 
inhibitor could be used as a primary preventative measure in healthy women or more of a 
secondary role in patients with pre-malignant lesions or patients on an established chemotherapy 
regimen. 
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 Angiogenesis is defined as the recruitment of new blood vessels, a normal occurrence 
during development.  It serves a much more restricted purpose in adults.  It is involved in tissue 
regeneration and in chronic inflammatory conditions in adults.  Cancer cells can promote 
angiogenesis in two manners.  First in early tumorigenesis, oncogene-driven tumor expression 
proteins can be expressed to begin the process of blood vessel formation.  Another method of 
activation comes from the hypoxic conditions in the center of the tumor.  This can lead the cell to 
activate hypoxia-inducible factors, which leads to angiogenesis. 
Inhibitors fall into two classes, either direct or indirect (Shaked and Kerbel 2007).  Direct 
inhibitors prevent the endothelial cells from proliferating, migrating or avoiding cell death in 
response to a wide array of pro-angiogenesis growth factors.  This would lead one to believe that 
direct inhibitors are less likely to develop resistance, due to the fact that they act on a more 
genetically stable cell.  It has been shown that tumors in mice have not become resistant.  
Indirect inhibitors are those that act on the tumor proteins that activate angiogenesis. 
The biological effect of anti-angiogenic drugs is an initial loss of tumor blood flow.  This 
can occasionally and briefly cause an increase in tumor size, but eventually the tumor submits to 
the hypoxic conditions due to the loss of blood flow and becomes an apoptotic mass.  Due to the 
brief history of these drugs, the full effect of their use has yet to be determined.  Although there 
have been indications that using them in conjunction with another drug may lead to the most 
beneficial results. 
The most commonly used angiogenesis inhibitors are Endostatin and Iressa.  Iressa, also 
known as ZD1839, is an indirect inhibitor that inhibits tumor synthesis of angiogenic protein such 
as bFGF, VEGF, and TGF-α.  Endostatin is a direct inhibitor, which inhibits endothelia cells from 
responding to multiple angiogenic proteins such as bFGF, VEGF, Il-8, and PDGF.  Its use has 
only been studied for a short period, but has thus far shown relatively low toxicity and patients 
have rarely acquired drug resistance. 
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 1.5 Prolactin 
Prolactin is a versatile hormone of the anterior pituitary gland that displays biological 
activities related to reproduction, behavior, and immunomodulation.  It is best know for its role in 
mammary gland development, where it is required for lobuloalveolar formation of the mammary 
ducts, terminal differentiation of the mammary epithelial cell, and synthesis of milk during 
lactation.  The prolactin gene, a single gene coded on chromosome 6, is approximately 10 Kb in 
size (Freeman, Kanyicska et al. 2000).  The gene is composed of 5 exons and 4 introns.  
Transcription is regulated by a set of independent promoter regions.  Pituitary-specific expression 
is controlled by a region 5000-bp upstream of the actual gene, while extra pituitary expression is 
controlled even further upstream. 
The human prolactin cDNA contains 914 nucleotides with a 614 nucleotide open reading 
frame encoding a prohormone of 227 amino acids (Sinha 1995).  Mature prolactin is composed of 
199 amino acids.  The molecule is arranged in a signal chain of amino acids with three 
intramolecular disulfide bonds between six cysteine residues (Freeman, Kanyicska et al. 2000).  
The study of the secondary and tertiary structure of prolactin have shown that 50% of the amino 
acids are arranged in four long α-helices in an anti-parallel fashion, while the rest form loops. 
While prolactin was given its name due to its involvement in growth and lactation of 
mammary gland cells, the molecule has a wide variety of other biological activities not related to 
its name from osmoregulation to angiogenesis to intersystem communication (Freeman, 
Kanyicska et al. 2000).  Prolactin has been shown to play a role in the regulation of the humoral 
and cellular immune response in both normal and diseased systems.  This could be due to 
involvement of prolactin in the mitogenesis of lymphocytes, which has been shown in T-cells 
(Viselli, Stanek et al. 1991) and Nb2 lymphoma cell lines (Shiu, Elsholtz et al. 1983).  Prolactin 
serum levels have been determined to play a role in skin graft rejections.  Elevated levels of 
prolactin have been shown to increase rejection incidence (Halmi, Parsons et al. 1975).  
Strengthening the case that prolactin is involved in the T lymphocyte response is data that 
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 prolactin serum levels decreased with bromcryptine prolongs the survival time of the transplants 
(Vidaller, Llorente et al. 1986). 
The prolactin receptor gene is coded on chromosome 5 and contains at least 10 exons 
(Hu, Zhuang et al. 1999).  Three different, tissue-specific promoters control transcription.  While a 
truncated short form is found in rats and mice, only the long and intermediate forms have been 
identified in humans.   The mRNA for the prolactin receptor has been found in many tissue types, 
such as uterus, kidney, liver ovary, and prostate (Peirce, Chen et al. 2001).  By far the greatest 
levels of the prolactin receptor are found in the breast. 
The prolactin receptor is a single membrane-bound protein that belongs to class 1 of the 
cytokine receptor super family (Freeman, Kanyicska et al. 2000).  Each receptor contains an 
extra-cellular, transmembrane, and intracellular domain.  Each extra-cellular isoform contains 
sequence of 210 amino acids.  The most conserved region of this domain is two pairs of disulfide 
bonds, which appear to be essential in the proper folding and trafficking of the receptor.  
Activation of the receptor actually occurs when a single prolactin molecule, which has two binding 
sites, is seated in the binding sites of 2 receptors.  The mutation of amino acid 129 in the prolactin 
sequence, replacing the normal Gly with Arg, disrupts the activation of the receptor by not 
allowing the second receptor to bind the prolactin molecule (Chen, Ramamoorthy et al. 1999). 
The 24 amino acid transmembrane domain’s role in receptor activation is unknown, but 
the intracellular domain plays a vital role (Bole-Feysot, Goffin et al. 1998). The region of the 
receptor proximal to the membrane is associated with Janus kinase 2 (Jak2).  Phosphorylation of 
the Jak2 molecule occurs within a minute of the first domain of prolactin binding to the receptor.  
However, activation of Jak2 does not occur until transphosphorylation of the molecule, once the 
trimeric receptor-prolactin-receptor complex is found in the extra-cellular domain. 
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 The activated Jak2 molecule activates the intracellular domain by phosphorylating a 
tyrosine residue on the prolactin receptor itself.  The phosphorylated tyrosine residue interacts 
with the SH2 domain of STAT3 and STAT5, phosphorylating these molecules.  Once the STAT 
proteins have been activated, they move to the nucleus and activate STAT DNA-binding motif in 
the promoter of the target gene.  A schematic representation of PRL signaling can be found in 
Figure 1.2. 
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Figure 1.2.  PRL Signal Transduction.  PRL binding to PRLR induces receptor phosphorylation 
and the association of several signaling pathways necessary for PRL action.  Represented here 
is a schematic representation of the JAK/STAT, Pi3K/AKT, and Ras/Raf MAPK pathway 
activation by PRL. 
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 While activation of the Jak/ STAT pathway is considered the most important pathway 
initiated by the activation of the prolactin receptor, the mitogen-acticated protein (MAP) kinases 
cascade has also been implicated (Goffin, Binart et al. 1999).  The phosphorylated tyrosine 
residues can also serve as docking sites for adapter proteins, Shc, Grb2, and Sos, which connect 
the receptor to the Ras/Raf/MAP kinase cascade.  This pathway also involves activation of 
transcription cofactors within the nucleus. 
Prolactin’s involvement in rodent breast cancer is quite controversial.  Pituitary isographs 
that secrete prolactin in large amounts have been shown to significantly increase the incidence of 
tumor development in mice [(Muhlbock and Boot 1959).  Injections of prolactin have resulted in 
greater tumor occurrence in mice treated with DMBA (Boot 1970).  However, the expression of 
extremely low amounts of prolactin in heterozygous HER-2 mice has been shown to delay tumor 
formation in this bigenic mouse model (Wen Y. Chen and Peirce 2007).  The function of prolactin 
in the etiology and progression of human breast cancer is still unclear (Vonderhaar 1999).  It has 
been known for some time that prolactin receptors are present in human breast biopsies, while 
prolactin itself can also be detected in human breast cancer biopsies.  While the literature 
suggests prolactin levels may influence breast cancer, there has yet to a clear correlation 
between either prolactin levels or prolactin receptor expression in the progression of the disease 
(Ingram, Nottage et al. 1990; Love, Rose et al. 1991). 
There is considerable evidence to the involvement of prolactin in the reduction of breast 
cancer.  As mentioned above, the mutation that replaces the Gyl amino acid at position 129 of the 
prolactin molecule with an Agr (G129R) (Chen, Ramamoorthy et al. 1999) has proven to be a 
useful agent in the fight against breast cancer.  The group demonstrated that the mutant protein 
induces apoptosis or programmed cell death.  The induction is observed through one of the 
hallmark apoptotic markers of internucleosomal DNA cleavage.  G129R has been shown to be 
more effective when given in conjunction with another anti-cancer treatment (Ramamoorthy, 
Sticca et al. 2001).  This study showed that use with Tamoxifen, a selective estrogen-receptor 
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 modulator (SERM) (Brown and Lippman 2000), there was a significant decrease in the number of 
cells when treating various cancer cell lines in vitro. 
Investigation into the mechanism of apoptosis induction revealed the G129R inhibits the 
phosphorylation of STAT3 (Cataldo, Chen et al. 2000).  Beck et. al. (Beck, Peirce et al. 2002) 
examined the expression of bcl-2 in relation to prolactin and hPRL-G129R levels.  Bcl-2 is a 
human proto-oncogene that when over-expressed, will ultimately lead to inhibition of cell death 
[(Korsmeyer 1999).   The prolactin molecule was shown to play a role in the regulation of the bcl-
2 gene.  Prolactin increased expression, while the hPRL-G129G decreased expression (Beck, 
Peirce et al. 2002). 
The utilization of G129R as a delivery molecule opens a variety of opportunities in the 
treatment of breast cancer.  Taking advantage of the overwhelming majority of breast cancers 
that over-express prolactin receptors, proteins can be fused with G129R to deliver a more potent 
drug directly to the tumor.  To utilize the body’s immune system, G129R was fused to interleukin 
2 (Il-2) (Zhang, Li et al. 2002).  There is ample evidence that tumor cells contain the antigens 
necessary to stimulate T lymphocyte (Urban and Schreiber 1992).  However, the cells lack the 
second messenger capabilities to activate the naïve lymphocytes.  Il-2 has been one of the 
primary cytokines used for treating cancer.  The cytokines main function is to stimulate 
differentiation and proliferation once the T lymphocyte has encountered its specific antigen via the 
major histocompatibility complex (Parham 2005).  G129R-Il2 has been shown to possess an 
inhibitory effect on cancer cell lines (Zhang, Li et al. 2002).  This study also demonstrated a 
reduction in tumor size by approximately one third in mice.  
To target the tumor’s agiogenic need, G129R was fused with the potent angiogenesis 
inhibitor endostatin (Beck, Chen et al. 2003).  The data demonstrated that this novel fusion 
protein was able to bind to the PRL receptor (PRLR) on T-47D human breast cancer cells and 
inhibit the signal transduction induced by PRL. At the same time, G129R-endostatin inhibited 
human umbilical vein endothelial cell (HUVEC) proliferation and disrupted the formation of 
endothelial tube structures with potency similar to that of endostatin. More importantly, the 
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 therapeutic efficacy of G129R-endostatin was confirmed using a mouse breast cancer cell line 
4T1 in vivo. G129R-endostatin has a significantly prolonged serum half-life as compared with that 
of G129R or endostatin alone, and exhibited greater tumor inhibitory effects than G129R and 
endostatin individually or in combination. 
A third multifunctional fusion protein was generated by fusing G129R to a truncated 
portion of Pseudomonas exotoxin A (Langenheim and Chen 2005).  It was demonstrated that the 
fusion toxin can competitively bind to hPRLRs on T-47D human breast cancer cells and inhibit 
STAT5 phosphorylation induced by hPRL. In addition, G129R-PE(40)-KDEL is selectively 
cytotoxic to breast cancer cell lines expressing hPRLR and that cell death is associated with the 
inhibition of protein synthesis and does not involve caspase mediated apoptosis. 
1.6 DMBA 
7, 12-Dimethylbenz(a)anthracene, more commonly known as DMBA, is classified as a 
polycyclic aromatic hydrocarbon (PAH).  DMBA is a by-product of the incomplete combustion of 
organic matter.  PAH’s, including DMBA, can be found in automobile exhaust, tobacco smoke, 
and can also be produced by pyrolysis of amino acids, fatty acids, and carbohydrates during 
cooking.  Its structure is composed of an anthracene backbone.  Numbering of the carbon atoms 
begins with the right-most ring.  Numbering proceeds clockwise around the molecule on the 
exterior atoms and then continues with the interior atoms on the second pass clockwise around 
the molecule.  Methyl groups are located on carbon atoms 7 and 12.   
 As part of many organisms’ natural elimination pathway, DMBA reacts with Cytochrome 
P450 (CYP) forming a variety of compounds.  These products are the carcinogenic compounds 
which bind to DNA to inflict their damage or react with phase II enzymes, which are eliminated 
from the organism.  DMBA has been shown to disrupt many molecular balances within cells and 
its effects are modified by various hormones, chemicals, and radiation. 
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 1.6.1 Phase I Reactions 
DMBA, as with other PAH’s, reacts with classical phase I cytochromes.  CYP1A1 or 
CYP1B1 phase I cytochromes have been shown to be the major enzymes with which DMBA 
reacts most readily (Casarett, Doull et al. 2001).   Recent studies have shown that DMBA will also 
react with recently characterized P450EF and P450RAP in specific conditions (Otto, Marcus et al. 
1991; Otto, Bhattacharyya et al. 1992).  The reaction of the phase I cytochrome and DMBA 
results in the formation of a highly reactive epoxide compound.  In the presence of Epoxide 
Hydrolase, the epoxide is further converted to diols.     
CYP1A1 is an extrahepatic enzyme readily detectable in the heart, lungs, intestine, skin, 
lymphocytes of cigarette smokers as a result of the by-products from the combustion of the 
tobacco.  DMBA has been shown to induce CYP1A1 via the aryl hydrocarbon receptor (AhR) 
(MacDonald, Ciolino et al. 2001).  By treating various cell lines with an AhR modulator, 
Dibenzotlmethane (DBM), the expression levels of CYP1A1 were decreased.  The observed 
decrease was thought to occur due to DBM’s ability to block the AhR active site from DMBA and 
prevent the CYP1A1 expression.   CYP1A1 has also been shown to be constituently expressed in 
human mammary epithelial cells (HMEC) in the range of 0.03-0.10 pmol/mg (Larsen, Angus et al. 
1998).  CYP1A1 exhibited a degree of regioselectivity.  When HMECs were treated with a 
CYP1B1 inhibitor, the major metabolic product generated was 8, 9-dihydrodiol of DMBA. Other 
studies have shown the production of the minor metabolic product 3, 4-dihydodio, 7-methoxy, as 
well as various phenols.  However, the levels of these products were from ½ to 1/14 the levels of 
major product 8,9-dihydrodiol (Savas, Carstens et al. 1997). 
CYP1B1 is the phase I enzyme of preference for DMBA.  It is constituently expressed 
throughout the body on the order of 16 pmol/mg (Larsen, Angus et al. 1998).  In the presence of 
DMBA, CYP1B1 is inducible via the AhR to levels 3 to 5 times that of serum levels.  CYP1B1 has 
been reported to have 5 to 10 times the affinity for DMBA as compared to CYP1A1 (Savas, 
Carstens et al. 1997).  The metabolic products produced from the reaction of DMBA and CYP1B1 
yield a much more even ratio of 5,6-dihydrodiol, 8,9-dihydrodiol, 10,11-dihydrodiol, 3,4-
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 dihydrodiol, and phenols  with only a small amounts of 7-methoxy detected.  It has also been 
shown that CYP1B1 determines the susceptibility to ovarian cancer in mice as well as DMBA-
induced lyphomas (Buters, Sakai et al. 1999; Buters, Quintanilla-Martinez et al. 2003) due to DNA 
adduct formation, which will be discussed later. 
P450RAP has been shown to metabolize DMBA in the adrenal gland, ovaries, and testis 
microsomes (Otto, Bhattacharyya et al. 1992).  P450EF has also been shown to metabolize 
DMBA, but only in the adrenal gland thus far (Otto, Marcus et al. 1991).  These two cytochromes 
were shown to be immunochemically distinct from the steriodogenic and hepatic cytochromes of 
the I, II, and III gene families, but were still closely related to one another.  Both enzymes catalyze 
the metabolism of DMBA with similar regioselectivity, with phenols as the major products of the 
reaction.  Other products included 5, 6-dihydrodiol, 8,9-dihydrodiol, 10,11-dihydro, 3,4-
dihydrodiol, but virtually no 7-methoxy. 
It should be noted that none of the phase I enzymes were shown to directly catalyze the 
formation of dihydrodiols.  These enzymes catalyze the formation of an epoxide intermediate, 
which is rapidly converted to the dihydrodiol by epoxide hydrolase.  The enantiomeric 
composition of the metabolically formed dihydrodiol is determined by the epoxidation of the 
cytochrome P450 isozyme (Yang 1988). 
1.6.2 Phase II Reactions 
 Gluathione-S-transferase (GST), glutathione peroxidase (GPx), superoxide dismutase 
(SOD) and catalase (CAT) were found to be activated in different degrees following DMBA 
treatment in mice (Saha and Das 2003).  These enzymes are classical phase II enzymes, which 
are used to increase the water solubility of a phase I product to increase the possibility for 
excretion (Casarett, Doull et al. 2001).  Studies have shown that DMBA decreases glutathione 
(GHS) levels, which leads to an increase in DMBA carcinogenesis (Cao, Wang et al. 2001; 
Johnson, Kaufmann et al. 2003; Kaufmann, Luo et al. 2003).  Glutamine (GLN) plays a critical 
role in many metabolic pathways and is the major energy source in rapidly dividing cells.  
Decreases in serum GLN levels have been correlated to decreases in GHS levels.  It has also 
 34
 been shown that DMBA decreases GHS levels.  Decreasing the GHS levels allow for the 
procarcinogenic DMBA metabolites to remain in the system longer, thereby increasing the 
possibility for damage to occur.  Oral administration of GLN can alleviate the decreased GHS 
levels, which in turn leads to an increase in the DMBA metabolites excreted, thus lowering the 
damage to the system. 
 NAD(P)H: quinone oxido-redutase1 (NQO1) deficiency has been shown to increase the 
susceptibility of DMBA carcinogenesis in mouse skin (Long, Waikel et al. 2001).  NQO1 is a 
phase II enzyme that catalyzes a two-electron reduction and detoxification of quinines and their 
precursors.  DMBA treated NQO1 knock-out mice developed skin tumors while no tumors were 
observed in the wild-type mice.  When using an initiator, tumors where observed in both mouse 
lines, but the NQO1 knock-outs tumors were larger in size.  While it is possible that NQO1 acts 
directly on DMBA metabolites, it is also possible that NQO1 acts to reduce the oxidative stress 
and/or stabilize p53 tumor suppressor, which is known to be involved in DMBA carcinogenesis 
(Medina, Ullrich et al. 2002). 
 Metallothionien (Mt), normally thought of as a metal scavenger, was demonstrated to 
modify the carcinogenesis of DMBA when used with 12-O-tetradecanoylphorbol-13-acetate (TPA) 
(Suzuki, Nishimura et al. 2003).  The cysteine residues contained in Mt are responsible for 
binding the heavy metals that can also be conjugated to DMBA phase I metabolites.  The 
treatment Mt-null mice with DMBA and the initiator TPA increased the tumor formation when 
compared to the tumor rate of the wild-type mice treated in a similar fashion. 
 The action of cancer chemopreventatives has been linked to enhancement of phase II 
detoxification enzymes.  4’-Bromoflavone decreases the potency of DMBA by increasing the 
expression of NQO1 (Song, Kosmeder et al. 1999).  Theaflavin, a component of black tea, 
enhanced the activation of GHT, GPx, SOD, and CAT by significantly reducing lipid peroxidation 
(Saha and Das 2003).  GST expression levels are nearly two fold higher in DMBA treated 
SENCAR mice when their diets are supplemented with coumarins.  Coumarins occur in many 
food sources, including citrus fruits, herbs, and vegetables.  Coumarins modify the phase I and 
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 phase II activities, especially that of GST.  This leads to a 23-48% decrease in DMBA-DNA 
adduct formation, depending on the tissue type (Kleiner, Vulimiri et al. 2001; Kleiner, Reed et al. 
2003). 
1.6.3 DNA Adduct Formation 
 DMBA inflicts damage upon the organism by binding to DNA and disrupting gene 
transcription.  Investigation using 3H-labelled DMBA to treat rodents has revealed DMBA-DNA 
adduct formation in heart, lung, liver, mammary gland, and adrenal gland (Das, Delp et al. 1989; 
Izzotti, Camoirano et al. 1999; Granberg, Brunstrom et al. 2000; Lindhe, Granberg et al. 2002).  
Using mouse mammary cells transformed by DMBA in organ culture three major adducts were 
identified.  Anti-3,4-diol-1,2-epoxide (DMBADE):deoxyguanosine, syn-DMBADE:deoxyadenosine, 
and anti-DMBADE:deoxyadenosine were  the DNA adduct formation products observed.  
Chemopreventative agents were able to cut the DMBA-DNA adduct formation by 50% in liver 
cells.  This did not prove to be true in mammary cells, which is consistent with a decrease in 
phase II activities in the mammary gland.  Increased radioactive labeling was observed in the 
endothelial cells of the heart, lung, and liver.  The addition of CYP1A1 inhibitors abolished the 
binding in the endothelial cells, while mice given CYP1A1 inducers revealed an increase in DNA 
binding.  Observations within the adrenal gland revealed DMBA-DNA adduct formation in the 
parenchymal cells was catalyzed by CYP1B1, while CYP1A1 followed the trend observed in the 
heart, lungs, and liver by increasing binding in the endothelial cells.   
 Stable DMBA-DNA adduct formation was determined to be a function of the metabolic 
activation of the bay region within the DMBA molecule (Melendez-Colon, Luch et al. 2000).  The 
bay region contains carbon atoms 1, 13, 12, and 18, with the methyl group located on carbon-12 
sterically hindering the bay region.  The 1,2-diol formation at the outer edge of the bay region is 
predominantly responsible for the DNA damage, rather than  radical cations via one-electron  
oxidation reactions. 
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 1.6.4 Mammary Tumor Formation 
 DMBA has been used as a model for mammary cancer for over 5 decades.  Originally 
characterized in rats (Geyer, Bleisch et al. 1951; Huggins, Grand et al. 1961), a single oral 
administration of 80-100 mg/kg consistently induced ductal mammary carcinoma in pubertal rats.  
Treating 56-day-old virgin rats will yield 75 to 100% tumor rate within 2 months of the 
administration of DMBA.  As alluded to earlier, this is possibly due to the decrease in phase II 
components due to the rapid cell growth of the region in that time period.  
 Characterization of the tumors developed in mice was performed in the late 1970’s and 
early 1980’s.  The tumor begins with a preneoplastic lesion (Medina 1976) or a collection of 
morphologically discrete epithelial lesions that are altered from normal condition.  Hyperplastic 
alveolar nodules (HAN) are one such example.  HAN are described in DMBA-fed rodents and 
give rise to adenocarcinomas.  Lin, et. al. demonstrated that cell-cycle could effect the formation 
of HAN in 1976.  Mammary gland organ cultures, stimulated via hormone treatment to grow in 
various states of proliferation and differentiation, revealed that cultures in a simulated state of 
lobular development or lactation were more likely to form HAN than cultures undergoing 
simulated involution. 
 DMBA tumor rates in mice are much more variable than those of the rat.  Strain, age and 
genetic modification can alter the rate and time course of the disease.  Ethier and Ullrich 
performed a dose study on virgin BALB/C mice in 1982 (Ethier and Ullrich 1982).  Single low 
doses, similar to that given a rat, yielded only 17 to 35 % tumor incidence with the study 
continuing for over 2.5 years.   Increasing to multiple doses accumulating to approximately 6 mg 
of DMBA yielded approximately a 50 % tumor incidence within 1.5 years.  Virgin C57BL mice 
treated with multiple doses accumulating to 6 mg of DMBA induced mammary tumors at a rate of 
69 % within 50 weeks (Medina, Butel et al. 1980).  This study also demonstrated that the rate 
could be increased and the latency period decreased through hormone stimulation, thus placing 
the gland in a more rapid rate of growth. 
 
 37
 1.6.5 Alterations of Gene Expression 
DMBA has been shown to modify the expression of classical cancer cell immortalization 
molecules, such as H-ras and telomerase.  Mutations of the H-ras gene occurred in 92 % of 
DMBA induced mammary tumors, whereas none of the spontaneously occurring mammary 
tumors contained the H-ras mutations (Kumar, Medina et al. 1990).  The research group showed 
that the mutation was limited to the 61st codon with a substitution of a T or G for A181.  The syn-
dihydrodiol epoxide is thought to be the most likely ultimate carcinogen due to its relatively bulky 
adenosine adduct formation observed in the region. 
Telomerase is a ribonucleoprotein complex intimately involved in cell immortalization and 
carcinogenesis.  This enzyme is activated and stabilizes telomere length in almost all types of 
cancer.  Telomerase may be necessary for continuous cell proliferation.  Telomerase activity in 
hamster experimental oral lesions evoked by 7,12-dimethylbenz[a]anthracene were analyzed 
(Sumida, Hamakawa et al. 1999).  Histologically normal epithelium expressed weak telomerase 
activity. The telomerase activity count increased rapidly in the early stage of carcinogenesis and 
gradually in the later stage.  The consequences of telomerase activation are that the telomere 
never reaches a length short enough to induce apoptosis. 
 The carcinogenesis of DMBA within the mammary gland has been shown to be critically 
dependant on the progesterone receptor (PR) (Lydon, Ge et al. 1999).  Progesterone receptor 
knockout (PRKO) mice treated with DMBA showed a marked reduction in mammary tumor 
incidence as compared with rate of isogenic wild types (WT).  
 The associations between growth hormone (GH) levels and tumor incidence have been 
well documented (Werner and LeRoith 1996).  The in vivo investigation of the relationship 
between physiological changes in plasma GH in DMBA-induced carcinogenesis revealed that 
GH-deficient mice were resistant to the carcinogen (Ramsey, Ingram et al. 2002).  When 
supplementing the GH-deficient mice with GH, the mice begin exhibiting a tumor incidence in a 
dose dependent manner.    Lending further evidence to the relationship between GH and tumor 
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 formation, a GH antagonist has been shown to reduce mammary gland carcinogenesis when 
administered to DMBA treated mice (Pollak, Blouin et al. 2001). 
 DMBA is a potent carcinogenic compound.  It must first be chemically modified by phase 
I enzymes such as CYP1A1, CYP1B1, P450EF and P450RAP.  DMBA-phase I metabolites 
further react with phase II enzymes such as GST, SOD, CAT and NQO1 to be eliminated from 
the system.  However, should the phase II enzymes be suppressed, limited, or modified, the 
phase I metabolites can bind directly to DNA leading to mutations or alterations of gene 
expression.  DMBA has been shown to modify a variety of proteins including H-ras and 
Telomerase, while also working under the influence of several hormone systems such as 
Estrogen, Progesterone and GH.  There are numerous other compounds, both naturally occurring 
and synthetic, that enhances the phase II enzyme system,   thereby decreasing the susceptibility 
of DMBA-induced carcinogenesis. 
1.7 Mouse Models of Cancer 
 The laboratory mouse is one of the best models for studying cancer due to its small size, 
short life span, physiological and molecular similarity to human and a sequenced genome.  
Mouse cancer models have progressed through many phases over the years increasing in 
complexity from xenografts to chemical and viral carcinogens and finally to genetically engineered 
mice.  Each model has its inherent advantages and disadvantages, and the choice of the 
appropriate system must come from the particular question one is looking to answer in the 
experiment. 
1.7.1 Xenografting 
 Cell lines established from human and animal tumors have led to the description and 
discovery of transforming genes, laying the foundation for cancer biology.  However, many initial 
observations are being re-evaluated due to the appreciation of cancer as a complex disease.  
The intricate interaction between the cell autonomous compartment and the non-cell autonomous 
constitutes, including normal, stromal, and immunes cells, cannot be evaluated in cell culture 
(Hanahan and Weinberg 2000).  Improvements in biostatistics, tissue sampling, and genomics 
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 have allowed a more direct characterization of primary tumors.  However, contributions of the 
entire body are still not taken into account. 
 The xenograft model has enabled researchers to rapidly test compounds in vivo.  This 
model involves the implantation of cell line or tumor tissue into mice (Kendall, Adam et al. 2006).  
While there have been proposals of patient specific models, several crucial factors must be 
addressed before comparisons of autochthonous tumors can be compared to human tumors.  
Aspects of the tumor microenvironment in the xenograft are altered or even lost.  These include 
vasculature and lymphatic circulation, immune and stromal cells, and even normal adjacent tissue 
within the tumor (Sikder, Huso et al. 2003; Becher and Holland 2006).  The uniformity of the 
cellular composition within the tumor is the most misrepresented feature of the tumor 
microenvironment (De Both, Vermey et al. 1997; Kang, Siegel et al. 2003).  The therapeutic 
evaluation of compounds is likely hindered by these differences, as drugs with demonstrated 
abilities to hinder the growth of xenografts frequently show limited response in the clinical setting 
(Johnson, Decker et al. 2001).  This leads to the conclusion that xenografts should only be 
considered an intermediate step between cell culture and a mouse cancer model. 
 One improvement to the xenograft model has been the development of labeled tumor 
cells.  These cells stably express green fluorescence protein (GFP), red fluorescence protein 
(RFP), or firefly luciferase (Cao, Li et al. 2005; Kashiwagi, Izumi et al. 2005; Duda, Cohen et al. 
2006; Kisucka, Butterfield et al. 2006), which can be used to visualize tumor growth and 
metastasis in vivo during the study.  These models are still hampered by the usual disadvantages 
on xenograft models, such as the clonal nature of the tumors misrepresenting the original 
disease.  However, the development of GFP-expressing transgenic mice has offered some 
assistance in the study of disease progression in the xenograft model (Yang, Li et al. 2003).  This 
mouse model enables the scientist to xenograft cells stably expressing GFP and visualizes the 
tumor-host interactions using whole body dual-color fluorescence imaging.  Tumor cells are 
distinguished from the host vascular system, infiltrating cells, and stromal cell allowing a 
previously unattainable look at tumor-host interaction.   
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  Another method, recently developed, addresses the clonal nature of the xenograft.  This 
model makes use of mesenchymal stem cells (MSCs) (Karnoub, Dash et al. 2007).  The authors 
demonstrate that the MCSs can expedite tumor metastasis.  This suggests that after primary 
human carcinomas recruit MSCs populations into their mix, demonstrated by venous injections of 
MSCs into mice with established non-metastatic tumors, and subsequent interactions between 
the tumor cells and MSCs (or other mesenchymal cell or derivatives) the MSCs bestow invasive 
and metastatic properties.  The authors also demonstrated that this metastatic potential was 
dependant on the presence of MSCs, as the transplantation of metastasized tumors into new, 
healthy mice generated no further metastatic colonies.  This suggests that many cellular functions 
associated with increased metastasis and invasions are often not expressed constitutively by the 
tumor cells, but rather in response to their interaction with stromal cells.  The consequence of 
which is that the determination of the genes and proteins involved in invasion and metastasis will 
need to focus on stromal signals rather than those directly mediating the cellular phenotype of the 
metastatic cells. 
1.7.2 Environmentally Induced Models 
 The next phase in mouse cancer model increases the complexity of the experiments.  
Certain strains of mice have an increased susceptibility to develop spontaneous tumors when 
exposed to the insult of chemicals (Balmain and Pragnell 1983), radiation (van Kranen, de Gruijl 
et al. 1995), or viruses (Cardiff and Kenney 2007).  These models have been useful for identifying 
oncogenes and tumor suppressor genes, mapping tumor susceptibility traits, and most 
importantly assessing carcinogen and chemopreventative effect of various compounds.  One 
such agent, DMBA, was thoroughly reviewed in the previous section.  However, the lack of tumor 
type and grades, incomplete penetrance of the tumors, and the variable latency limit this model 
as a model to evaluate therapeutic agents. 
1.7.3  Genetically Engineered Models 
 Genetically engineered mouse models are the most sophisticated animal models of 
human cancer.  Many models now exist that provide an accurate mimic of the pathophysiological 
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 and molecular feature of human cancers.  Genetically engineered models fall into one of two 
categories.  The first is classified transgenic models, which the oncogene or tumor suppressor 
genes are expressed in non-physiological manner under the control of an ectopic promoter or 
enhancer element.  These models have been used to demonstrate the requirement of Hras, Kras, 
Myc, Bcr-Abl, and HER-2 in the maintenance of melanoma (Chin, Tam et al. 1999), lung cancer 
(Fisher, Wellen et al. 2001), acute myeloid leukemia (Felsher and Bishop 1999), and breast 
cancer (Moody, Sarkisian et al. 2002). 
 While the first transgenic mice where generated by infecting the mouse embryos with a 
retrovirus (Jaenisch 1976), the technique of choice is pronuclear injection (Gordon, Scangos et al. 
1980).  Here foreign DNA is injected into the pronucleus of a fertilized egg.  The stable 
incorporation of the transgene into the genome leads to the expression of the protein and 
transmission of the gene to offspring.  Although this method is widely used, some disadvantages 
have been reported (Auerbach 2004).  For example, the production of transgenic mice occurs 
with extremely low efficiency.  The insertion point of the transgene has been shown to influence 
expression and ultimately the phenotype differences observed when comparing different founders 
(Palmiter, Chen et al. 1982).  Therefore, it is generally recommended that several founders be 
independently generated from the same construct to provide an array of expression levels and 
observe any differences in phenotype that may occur. 
 To control expression in the transgenic mouse, several promoter systems have been 
developed.  A ubiquitous promoter system which utilizes the cytomegalovirus (Furth, 
Hennighausen et al. 1991) can express the transgene in all tissues, but markedly different 
expression level can be found in different tissues.  Tissue specific promoter systems have also 
been devolved.  The mouse mammary tumor virus long terminal repeat (MMTV) (Stewart, 
Pattengale et al. 1984) provides expression in the mammary gland throughout the life span of the 
animal.  Another example is the whey acid protein (WAP) promoter system (Hennighausen 2000), 
which does not express the transgene until the mammary gland undergoes differentiation in 
preparation for lactation.   
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 More sophisticated systems have also been developed that express the transgene only 
when induced by an external agent.  The most widely used takes advantage of the tetracycline 
operon (Kilby, Snaith et al. 1993).  Here tetracycline or its non-toxic analog can be fed to the 
animal to either induce or inhibit transcription of the transgene.  Another commonly used and 
more complicated inducible system is the Cre-recombinase system.  To induce expression, the 
transgene is separated from the promoter by a recombination-activated gene expression cassette 
which contains stop codons in all reading frames, which are flanked by a LoxP sites.  The 
induction of Cre-recombinase, in vivo, will cause the excision of the recombination-activated gene 
expression cassette at the LoxP sites and expression of the transgene can commence.  The 
inactivation of the transgene in this system occurs by flanking a critic exon with the LoxP sites, 
thereby generating a nonfunctional protein when the Cre-recombinase expression is induced.  By 
placing the Cre-recombinase under the control of a tissue-specific or inducible promoter, the 
transgene expression can be further controlled and a more focus examination of the transgene 
expression can occur. 
 The second class of genetically engineered mice is referred to as endogenous mice.  
Here the tumor suppressor gene is lost or express dominate negative tumor suppressor genes or 
oncogenes from their native promoters (Gannon, Gamer et al. 2001).  Typically these models are 
referred to as gene knockouts and entail the replacement of endogenous embryonic stem cell 
chromatin by a targeting vector that disrupts the native allele.  These models are typically 
homozygous for the null allele in the germline and have proven to be beneficial in the study of 
inherited disease (Kuhn and Schwenk 2003).  The first knockouts were Rb1 and p53 tumor 
suppressors (Jacks, Fazeli et al. 1992; Jacks, Remington et al. 1994).  Since there inception, the 
knockout strategy has been refined and condition knockouts have been developed under the 
control of the Cre-LoxP system. 
 A number of mouse systems exist to study the pathogenesis of breast cancer.  At the 
basic level, there are models which over-express specific gene targets, normally under the control 
of mammary gland specific promoter systems.  Examples include the c-myc and HER-2 proto-
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 oncogenes.  There are also losses of function examples which include the p53 tumor suppressor 
transgenic mouse lines.   More complex systems, utilizing the techniques described above have 
been utilized to generate bigenic as well as knock-in and conditional tissue specific gene 
targeting strategies to better simulate the human disease. 
 Any number of promoters have been utilized to study the effects of transgene expression 
in the mammary gland, including metallothionein, beta-lactalbumin, and tetracycline.  However, 
there are two systems that encompass the majority of work on the mammary gland.  First is the 
MMTV-LTR.  This promoter is active throughout development with transcriptional activity 
increasing during pregnancy (Pattengale, Stewart et al. 1989).  The second is the whey acidic 
protein promoter.  This system only expresses the transgene during mid-pregnancy mammary 
glands.  These two systems can be utilized to explore the effect of transgene expression at 
various times during development. 
 The c-myc gene has been studied under several investigators under the control of both 
the MMTV-LTR and WAP promoters.  Under the MMTV-LRT promoter mammary tumor arose at 
anywhere from 4 to 19 months, depending upon the investigator (Escot, Theillet et al. 1986; 
Whorwell, Houghton et al. 1992; Bieche and Lidereau 1995).  The mice developed spontaneous 
adenocarcinomas in most cases, and locally invasive tumors in others.  The interesting 
information gleaned from these studies was that c-myc expression was detected in several other 
tissues in the body, despite the mammary gland specific promoter system.  However, mice 
developed a limited subset of tumors outside of the mammary gland.  The WAP promoter system 
has also been used to study the elevated c-myc expression in the mammary gland 
(Schoenenberger, Andres et al. 1988).  Here, 80% of the female mice developed multiple tumors 
affecting single or multiple glands after two pregnancies.  Together these studies demonstrate the 
c-myc can induce mammary tumors when over-expressed in the mammary gland.  The 
transformation does not occur in the entire gland, which leads to the conclusion that additional 
genetic defects must occur before the tumors are formed. 
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  Over-expression of cyclin D1 within the mammary gland has been studied using the 
MMTV-LTR promoter system.  These animals develop proliferative abnormalities in the mammary 
gland leading to focal mammary tumors (Wang, Cardiff et al. 1994).  The long latency and tumor 
development suggest that cyclin D1 over-expression can promote tumorigenesis, but once again 
additional genetic events are required for carcinoma development. 
 One of the most studied breast cancer models is the HER-2 receptor tyrosine kinase 
member of the EGFR family.  The family consists of four closely related type 1 receptor tyrosine 
kinases that include EGFR, Her2, ErbB-3(Her3), and ErbB-4 (Her4) (Hynes and Stern 1994).  
HER-2 is an orphan receptor whose signal is activated via the formation of receptor homo or 
hetero-dimers.  The dimerization results in phosphorylation of tyrosine residues on the receptor 
which serve as docking sites for SH2 and SH3 domains of various molecules that are able to 
further transduce signal (Hynes and Stern 1994; Dankort and Muller 2000).  The importance of 
HER-2 in human breast cancer has been previously discussed, but is highlighted by the fact that 
20-30% of human cancers over-express the receptor and its over-expression is correlated with an 
aggressive phenotype.  Therefore, studying this receptor’s over-expression in transgenic mice 
has been of keen interest. 
 Several lines of HER-2 mice have been developed, mostly under the control of the 
MMTV-LTR promoter system.  Mice carrying the transgene develop adenocarcinomas that are 
histologically similar to human comedocarcinomas (Muller, Sinn et al. 1988; Cardiff and Muller 
1993; Stocklin, Botteri et al. 1993; Guy, Cardiff et al. 1996).  While these models process a similar 
activating mutation, the more relevant model may be the wild type Her2 cDNA under the control 
of the MMTV-LRT promoter (Guy, Webster et al. 1992).  This system has been shown to develop 
focal mammary tumors with the comedocarcinoma-type morphology.  They develop these tumors 
on an average of 7 months and investigation of the HER-2 status revealed that sporadic 
mutations of the receptor leading to constitutive activation (Siegel, Dankort et al. 1994).  Another 
similarity tumors of these mice share with the human disease is that the elevated levels of HER-2 
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 tyrosine phosphorylation is frequently associated with elevated ErbB-3 transcripts (Siegel, Ryan 
et al. 1999). 
 Transgenic mouse models are also being utilized to investigate multi-step 
carcinogenesis.  Here existing transgenic mouse lines are crossed with one another to study the 
role of multiple oncogenes or tumor suppressors on tumor formation.  One of the first examples of 
this approach was crossbreeding the MMTV-c-myc mouse with the MMTV-v-Ha-ras mouse (Sinn, 
Muller et al. 1987).  This experiment demonstrated that c-myc and Ras could cooperate to 
accelerate mammary cancer.  However, the focal nature of the tumors, and the latency periods 
still suggest the further genetic events were required for transformation.  The crossing of the 
MMTV-c-myc mouse with a MMTV-TGF-α mouse decreased the tumor latency by nearly one fifth 
and demonstrated that those two signals were sufficient to induce mammary tumorigenesis 
(Amundadottir, Johnson et al. 1995). 
 Much has also been learned about HER-2 signaling in breast cancer through the use of 
transgenic mice.  For instance, the constitutive activation of the receptor is required for tumor 
formation.  The crossing of the MMTV-TGF-α mouse to the MMTV-neu mouse led to decreased 
tumor latency and the entire mammary gland became malignant (Muller, Arteaga et al. 1996).  It 
was observed in this study that HER-2 did not develop any mutations, rather the TGF-α is thought 
to have forced dimerization and trans-phosphorylation of EGFR (the receptor for TGF-α).  A role 
for ER has also been demonstrated in HER-2 tumorigenesis via MMTV-neu MMTV-aromatase 
double transgenic mice (Tekmal, Nair et al. 2007).  Here tumor incidence was decreased from 
65% (MMTV-neu) to 5% (double transgenic).  Cyclin D1 has also been shown to play a critical 
role in MMTV-neu tumorigenesis.  Mice lacking cyclin D1 were crossed with both MMTV-neu and 
MMTV-v-Ha-ras transgenic mice and in both cases the animals lacking cyclin D1 were resistant 
to tumor formation (Yu, Geng et al. 2001).  The group also reported that mice double positive for 
cyclin D1 and either c-myc or Wnt-1 were unaffected by the lack of cyclin D1 expression. 
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 1.8 Objectives 
 The work presented here is a double pronged approach to using a human prolactin 
antagonist for breast cancer therapy.  First, the use of G129R as a chemopreventative agent is 
investigated.  The in vivo data presented is a continuation of the group’s previously published 
work on G129R’s ability to slow the growth of breast cancer cell in vitro and in nude mouse 
xenografts. Second is to determine any benefits of using G129R based fusion proteins in 
combination as breast cancer therapies.  This study utilized a very unique model system, which 
much more closely resembles the clinical setting than traditional xenografting techniques. 
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 CHAPTER TWO 
 
THE ROLE OF HUMAN PROLACTIN AND ITS ANTAGONIST, G129R, ON MAMMARY 
GLAND DEVELOPMENT AND DMBA INITIATED TUMORIGENESIS IN TRANSGENIC MICE 
 
This chapter represents work published November 2005 in International Journal of Oncology 
(27(5):1381-9, 2005). 
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 2.1 Abstract   
Human prolactin (hPRL) has been implicated to have a pathological role in breast cancer 
and play a critical role in mammary gland development.  The hPRL antagonist, G129R, has been 
shown to induce breast cancer cell apoptosis.  9,10-Dimethyl-1,2-benzanthracene (DMBA), a 
potent mammary gland carcinogen, induces hormone responsive mammary tumor formation in 
rodents.  To investigate the effects of hPRL and its inactive counterpart, G129R, on mammary 
gland development and tumorigenesis, transgenic mice that express hPRL or G129R under the 
regulation of the metallothionein (Mt) promoter were generated.  Mammary glands from virgin 
female transgenic mice at ages 12-, 24-, and 36-weeks were used to compare the effect of hPRL 
and G129R in various developmental stages.  Mammary gland whole mount comparisons 
between the transgenic mice and their littermates revealed a significant increase in ductal 
branching and lobular bud formation in the hPRL transgenic mice; whereas a drastic decrease in 
ductal branching and lobular bud formation was observed in the mammary glands of G129R 
transgenic mice.  In addition, total RNA isolated from the mammary glands from different 
transgenic mice at three age groups was analyzed on Affymetrix GeneChip Mouse Expression 
430A chips (MOE430A).  Microarray data revealed alteration to the gene expression levels 
greatest at 12 and 36-weeks.  Furthermore, hPRL and G129R transgenic mice as well as their 
littermates were treated with multiple doses of DMBA and the rate of mammary tumor formation 
and survival were compared.  The tumor rate in the G129R transgenic mice was significantly 
reduced (18% at 28-weeks) as compare to that of either NTG (39%) or hPRL (40%).  On the 
other hand, the tumor appearance is significantly earlier in PRL transgenic group as compare to 
that of controls.  Taken together, the data further confirm the inhibitory effects of G129R in 
mammary gland development which translates to a resistance to DMBA initiated breast 
tumorigenesis. 
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 2.2 Introduction 
DMBA has been shown to induce mammary tumor formation in rodents and has been 
used as a carcinogen for establishing mammary cancer models for over five decades.  Originally 
characterized in rats (Geyer, Bleisch et al. 1951; Huggins, Grand et al. 1961), a single oral 
administration of 80-100 mg/kg consistently induced ductal mammary carcinomas in pubertal 
rats.  Administration of DMBA to 56-day-old virgin rats has been shown to yield 75 to 100% tumor 
formation within 8 weeks.  Characterization of DMBA-induced tumors in mice was performed in 
the late 1970’s and early 1980’s.  Tumor formation begins with a preneoplastic lesion or a 
collection of morphologically discrete epithelial lesions that are altered from normal condition 
(Medina 1976).  It has also been demonstrated that cell-cycle could affect the formation of HAN.  
Mammary gland organ cultures, stimulated via hormone treatment to grow in various states of 
proliferation and differentiation, revealed that cultures in a simulated state of lobular development 
or lactation were more likely to form HAN than cultures undergoing simulated involution (Lin, 
Banerjee et al. 1976). 
The majority of mammary gland development in mice occurs postnatally at the onset of 
puberty.  The prenatal glands consist primarily of a stromal fat pad with rudimentary ducts that 
are lined with epithelial cells.  Development of these ducts into a functional gland starts at 
approximately three weeks of age and is primarily controlled by steroid and peptide hormones 
produced by the ovary and pituitary gland (Sakakura, Kusano et al. 1987).    At this stage, the 
ductal work within the gland begins to advance through the fat pad and branch, forming an 
elaborate ductal tree with alveolar end buds (Silberstein 2001).  At an age of approximately 12-
weeks, the ductal work has reached the limits of the fat pad and the terminal end buds regress 
slightly awaiting the stimulation from hormones secreted during pregnancy.   During pregnancy a 
massive amount of differentiation and proliferation occurs in the mammary gland in preparation 
for lactation upon birth of the young.  This period is followed by involution, a process of 
substantial cell death once the young are weaned and the gland is no longer required for 
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 lactation.  Prolactin (PRL) is one of the main hormones intimately involved in the regulation of 
these physiological processes in the mammary gland. 
Prolactin was originally identified as a pituitary hormone that stimulates lactogenesis 
(Riddle O 1933).  The function of PRL has been extensively studied, especially in the past 
decade (Hennighausen, Robinson et al. 1997; Horseman 1999; Clevenger and Kline 2001).  Cell 
culture studies have shown that PRL is a vital component necessary to stimulate the proliferation 
of mammary epithelial cells (Darcy, Shoemaker et al. 1995).  In vivo, PRL has been shown to be 
required for the advancement of the ductal tree, formation of side branches and an increase in 
the amount of alveolar bud formation (Vomachka, Pratt et al. 2000; Saunier, Dif et al. 2003).  In 
previous studies it has been shown that a mutated hPRL with a single amino acid substitution 
mutation at position 129, G129R, is able to inhibit human breast cancer cell proliferation through 
the induction of apoptosis (Chen, Ramamoorthy et al. 1999).  The antagonistic effects of G129R 
are most likely through competitive inhibition of hPRL-induced Jak/Stat/MAPK signaling pathway 
that leads to a change of the expression ratio of the apoptotic and anti-apoptotic genes such as 
BAX and bcl-2 (Chen, Ramamoorthy et al. 1999; Llovera, Pichard et al. 2000; Beck, Peirce et al. 
2002; Peirce and Chen 2004).  
In the present study, the effects of prolonged, systemic expression of hPRL or G129R on 
the development of the mammary gland and their roles in DMBA induced tumorigenesis were 
investigated using transgenic mice.  The mammary glands from three different age groups were 
examined both at microscopic (whole mount) and genomic levels (Affymetrix microarray) with an 
emphasis on those genes related to PRL’s function.  To further address the relationship of 
carcinogen and hPRL in mammary tumor development and the role of G129R as a potential 
chemo-preventive agent, hPRL and G129R transgenic mice were challenged with multiple doses 
of DMBA and their rate of breast tumor formation was compared.   The tumor rate of the G129R 
transgenic mice was found to be significantly lower than that of non-transgenic mice whereas the 
tumor appeared significant earlier in the PRL transgenic group.   
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 2.3 Material and Methods 
2.3.1 Transgenic Animals 
Mt-hPRL and Mt-G129R cDNA were used to generate hPRL and G129R transgenic 
founder mice from the FVB strain (Jackson) by microinjection into single-cell embryos as 
described previously (Wagner, Hoppe et al. 1981; Chen, Wight et al. 1990).  Briefly, fertilized 
mouse eggs were flushed from the oviducts of superovulated FVB mice approximately 6 to 8 
hours following ovulation.  Male pronuclei of the fertilized eggs were injected with 2 ng/µL of DNA.  
Viable embryos were reimplanted in the oviducts of pseudopregnant mice.  After birth, the 
incorporation of the transgenes was confirmed by PCR using genomic DNA isolated from the tails 
of mice.  DNA was isolated from tail snips using DirectPCR Lysis Reagent (Viagen Biotech, Los 
Angeles, CA) according to the manufacturer’s instructions.  To confirm expression of the 
transgenes, RNA was extracted from mammary gland tissue that was frozen immediately 
following excision.  Approximately 50-100 mg of frozen tissue was homogenized on ice using a 
Polytron PT1200 motorized homogenizer (Polytron, Bad Wildbad, Germany) in 1mL Trizol 
(Invitrogen, Carlsbad, CA) and processed according to the manufacturer’s instructions.  The 
primers used in this study were as follows:  Mt-hPRL/G129R Mt for 5’-
CACGCTGCGAATGGGTTTACG-3’; hPRL/G129R for 5’-TGCTGCTGCTGGTGTCAA-3’;  hPRL 
rev 5’-CAGGATGAACCTGGATGACT-3’;  G3PDH for 5’-ACCACAGTCCATGCCATCAC-3’ and 
G3PDH rev 5’-TCCACCACCCTGTTGCTGTA-3’.  The resulting PCR products were resolved on 
a 1% agarose gel. 
The expression of the proteins in the serum was confirmed using a Coat-A-Count PRL 
IRMA Kit (Diagnostic Products Corporation) per manufacturer instructions.   The mammary 
glands were isolated from transgenic mice along with their age matched littermates at three 
different age groups (12, 24-28, and 36-48 weeks) for whole mount preparation or RNA extraction 
for microarray studies.  Whole mounts were prepared from freshly dissected tissue.  RNA was 
extracted from frozen mammary tissue. All animals were cared for in accordance with institutional 
guidelines for the care and use of experimental animals. 
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 2.3.2 DMBA Treatment 
DMBA (Sigma) was dissolved in corn oil to a concentration of 10 mg/mL.  Mice were 
anesthetized with 0.4 mg/g body weight of 2,2,2-tribromethanol (Aldrich) in tert-amyl alcohol 
(Sigma-Aldrich) and saline solution.  20 non-transgenic, 16 hPRL transgenic and 16 G129R 
transgenic mice were given 0.1 mL of the DMBA-corn oil stock (approximately 50 mg/kg body 
weight) by oral gavage.  This treatment was carried out once a week for five consecutive weeks.  
Mammary glands were palpitated twice a week until tumors were observed in the mammary 
glands of approximately 1 cm or the animals succumbed from other causes. Data analysis was 
performed using GB-Stat version 9.0 and Microsoft Excel™ . 
2.3.3 Mammary Gland Whole Mount 
The fourth inguinal mammary gland of control and transgenic mice was dissected and 
placed on a glass slide.  Tissue was fixed overnight in freshly prepared Carnoy’s fixative at room 
temperature.  The following day, the glands were systematically re-hydrated by decreasing the 
concentration of ethanol (Sigma) in ethanol /water solutions over a period of 2 hours.  The glands 
were placed in Carmine Alum Stain and allowed to stain overnight.  The glands were 
subsequently dehydrated by systematically increasing the concentration of ethanol in 
ethanol/water solutions over a period of 90 minutes.  The fat pad was cleared with xylene (Sigma) 
for approximately 30 minutes and a cover slip was secured with SecureMount (Fisher).  The 
glands were documented via digital photography and prepared for presentation with photo 
analysis software. Photographs were sectioned into 1 square mm grids and as many as 6 
sections per gland counted.  Results were averaged and a paired t-test was employed to 
determine significance. 
2.3.4 RNA Isolation 
Approximately 100 mg of mammary gland tissue was homogenized in 2 mL of cold 
TRIZOL (Invitrogen).  400 µL of chloroform (Fisher) was used to extract the RNA from the 
homogenate.  Samples were centrifuged at 12,000 times gravity for 15 minutes at 2º C.  RNA was 
precipitated from 300 µL of supernatant (aqueous phase containing RNA) by mixing 900 µL 
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 isopropyl alcohol (Sigma) and centrifuging again at 12,000 times gravity for 10 minutes at 2º C.  
Samples from four of the transgenic animals (hPRL or G129R) were pooled.  The control samples 
were prepared by pooling 2 non-transgenic littermates from each of the hPRL and G129R 
transgenic mouse lines.  The pooled samples were washed again with 1 mL of cold 75 percent 
ethanol and allowed to dry thoroughly.  The precipitated RNA was dissolved in 100 µL of DEPC 
water (ICN Biomedicals).  The 100 µL samples were purified with RNeasy Mini-spin columns 
(Qiagen) following manufacturer’s instructions.  The purity and quantity of each sample was 
assessed on an Agilent Technologies’ Bioanalyzer and the RNA 6000 Nano LabChip following 
manufacturer’s instructions.  Sample concentration was adjusted to approximately 1 µg per µL 
with DEPC water prior to shipment. 
2.3.5 Affymetrix Microarray 
Microarray studies were conducted by the Keck Affymetrix Resource Group at Yale 
University, which carries out sample processing, hybridization, and data analysis.  The GeneChip 
Mouse Expression 430A (Affymetrix) was employed to provide over 22,000 probe sets for 
analysis.  The Keck Affymetrix Resources Group performed all hybridization, quality control 
measures, as recommended by the Affymetrix protocols, in preparation of the cRNA for 
microarray analysis.  Scanned output files were visually inspected for hybridization artifacts and 
subsequently analyzed using Affymetrix Microarray 5.0 (MAS) software, per manufacturer’s 
instructions.  Signal to log ratios were generated by comparing the control to both the hPRL or 
G129R transgenic samples at each time point.  Microsoft Excel™ was utilized to examine 
changes in the expression patterns of the genes of interest. 
2.4 Results 
2.4.1 Trasgene Presence and Expression in Transgenic Mice 
Presence of the hPRL or G129R transgenes was confirmed by performing PCR on 
genomic DNA isolated from tail biopsies (Figure 2.1A).  Expression of these transgenes was also 
confirmed by RT-PCR using RNA extracted from mammary tissues of the mice (Figure 2.1B).   
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Figure 2.1.  Transgene presence and expression in transgenic mice.  Transgene presence and 
expression was confirmed in single and bitransgenic mice by (A) PCR and (B) RT-PCR using 
primers specific for hPRL or G129R sequences. (A) PCR products from the MT-hPRL and G129R 
groups (primers between MT promoter and hPRL or G129R cDNA) resulted in a 1002 bp 
fragment when resolved on a 1% agarose gel and stained with ethidium bromide.  (B) 
hPRL/G129R specific primers were used for RT-PCR to confirm the transcriptional expression of 
hPRL and G129R in the mammary gland. G3PDH was used as an internal control for DNA and 
RNA quality, and gel loading 
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 As expected, approximately 50% were positive for either hPRL or G129R.  Serum hPRL was 
measured using an hPRL IRMA, specific for hPRL, and which does not cross-react with 
endogenous mouse PRL.  Approximately 5 to 10 ng/ml of hPRL was detected in the serum of 
MT-hPRL or MT-G129R mice, as previously reported (Peirce and Chen 2004). 
2.4.2 Mammary Gland Whole Mount Studies 
The mammary gland ductal structure comparison between the hPRL, G129R transgenic 
mice and their non-transgenic (NTG) littermates at three different ages is shown in Figure 2.2.  
Examination of the mammary glands at 12-weeks showed similar degrees of ductal elongation 
and density.  However, upon closer examination the amount of bifurcation varied between the 
hPRL and G129R lines.  With increasing age, the majority of ducts lost the end bud structures 
and were replaced with a long tapered ductal end in the G129R line, similar to the mammary 
gland phenotypic change observed in PRL or PRL-R gene knockouts (Vomachka, Pratt et al. 
2000; Saunier, Dif et al. 2003).  The hPRL and their NTG littermates remained heavily budded 
with increasing age. 
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Figure 2.2.  Images of the fourth inguinal mammary glands of virgin mice after staining with 
Carnoy’s stain.  The glands were representative of the various time points used, 12-, 24- 
and 36-weeks where at least 3 different animals were observed.  Little difference was 
observed between the non-transgenic (NTG) littermates of either line; therefore, only one 
image of the non-transgenic littermates is shown. An increase in budding was observed in 
all PRL transgenic mice, while the G129R transgenic mice show a decrease in budding 
and development of tapered ductal end by 36-weeks as shown in the enlargements in the 
right-most column.  The 12-week hPRL and 36-week G129R showed the greatest 
phenotypic differences. 
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 To quantify the effect of the expression of either hPRL or G129R, the number of end 
buds per square millimeter for each group and time point were counted, as shown in Figure 2.3.  
When observing the individual lines through time, the G129R is statistically different, decreasing 
with age.  There was also a significant difference between 24- and 36-weeks in the PRL line, 
while the NTG line shows no significant difference in numbers at any time point.  At 12-weeks, 
there appeared to be no significant difference between the mouse lines.  However, all three lines 
were significantly different at 24-weeks and at 36-weeks the G129R was significantly different 
than NTG and PRL lines (Student t test, P<0.05). 
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Figure 2.3.  Quantification of the end buds formation in the mammary gland whole mounts 
(end buds per square millimeter).  Three glands from each line of transgenic mice and their 
littermates at three age groups were examined.  Digital images were sectioned into square 
millimeter grids and at least 6 grids were counted per photograph, values presented were 
the mean +/- STD.  Paired student t-test were employed to determine significance between 
any 2 groups with P<0.05 being a significantly value.  The G129R line was significantly 
different at each time point.  The hPRL line was significantly different as the mice age from 
24- to 36- weeks.  There was no difference between NTG littermates from different 
transgenic lines.  (*P<0.03 comparing individual line through time, ** P<0.05 comparing 
transgenic line at a time point) 
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 2.4.3 Mammary Tumor Induction by DMBA Treatment 
The oral administration of DMBA has been documented to be a potent carcinogen in 
rodents (Geyer, Bleisch et al. 1951; Huggins, Grand et al. 1961; Medina, Butel et al. 1980; Ethier 
and Ullrich 1982).  After administration of DMBA, a significant difference in the rate of mammary 
tumor formation between experimental groups was found (Figure 2.4).  The tumor rate in G129R 
transgenic mice was 18% (2/16) at 28-weeks as compared to 40% (4/16) of NTG and 39% of 
PRL transgenics after the initial dose of DMBA.  Although there was no difference in the tumor 
rates between the PRL transgenic group and the non-transgenic control after DMBA treatment as 
we had anticipated, the tumor appearance was significantly earlier than the control group, i.e.  it 
takes only 20 weeks for 40% of hPRL transgenic mice to develop tumor as compare to 26 week 
in control mice.  
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Figure 2.4.  Comparison of the breast tumor rates of DMBA treated mice.  Open diamonds 
represent data from the G129R transgenic mouse line, open squares from the non-
transgenic littermates, and closed squares from the hPRL transgenic line.  DMBA 
treatment was initiated when mice are approximately 12-weeks of age as indicated as time 
0.  The tumor rate in G129R transgenic mice was significantly reduced at 18% (2/16) as 
compared to 40% (4/16) of NTG and 39% (4/20) of hPRL transgenics at 28-weeks from the 
initial dose of DMBA in this line.  Significant difference from control determined by unpaired 
t-test with P< 0.01 was indicated with an asterisk (*). 
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 A high mortality rate in DMBA treatment was encountered, especially in hPRL and non-
transgenic group, which was obviously unrelated to mammary tumor formation.  The loss of 
experimental animals led to the termination of all experiments at 28-weeks post-treatment.  The 
Kaplan-Meier plot displayed in Figure 2.5 showed the effect of transgene expression on survival 
after DMBA administration.  The systemic expression of hPRL slightly improved the survival rate 
where 50% of the study group had expired by week 20 and the non-transgenic group rated this 
point by week 17.  The systemic expression of G129R significantly increased (P<0.0001) the 
survival rate of DMBA treatment, where 53% of the study group had survived to week 28 when 
only 38% survival was observed in the hPRL group and 20% of the non-transgenic group.  No 
significant difference was observable between the survival of the hPRL and non-transgenic 
groups. 
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Figure 2.5.  Kaplen-Meier Survival Analysis of the DMBA treated mice.  Open diamonds 
represent data from the G129R transgenic mouse line, open squares from the non-
transgenic littermates, and closed squares from the hPRL transgenic line.  DMBA 
treatment was initiated when mice are approximately 12-weeks of age as indicated as time 
0.  The survival rate of G129R transgenic mice after DMBA treatment was significantly 
increased (53%) as compared to 20% of hPRL or 38% of NTG group, respectively.  
Significant difference from control determined by unpaired t-test with P< 0.01 was indicated 
with an asterisk (*). 
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 2.4.4 Affymetrix Microarray 
To determine the molecular processes involved in the phenotypic changes observed in 
the whole mounts and elucidate the mechanisms involved in the differences in tumor formation 
between the mouse lines, the mammary gland gene expression profiles obtained from the hPRL 
and G129R transgenic mice were investigated.  Total RNA extracted from the mammary glands 
of the mice was hybridized to oligonucleotide microarrays representing approximately 22,000 
genes.  The mammary gland gene expression profiles from either hPRL or G129R transgenics 
were compared to the non-transgenic littermates via MAS 5.0 software from the Keck Laboratory.  
The signal to log ratio of the hPRL array was compared to the same data from the G129R array.  
In all, the number of genes significantly altered in both transgenic mouse lines was determined to 
be 839 at 12-weeks, 391 at 24-weeks, and 552 at 36-weeks.  The largest changes in the gene 
expression observed were in various cytochromes, transcription factors, T-cell mediators, and 
adhesion molecules. For presentation purposes, only the top twelve genes with altered 
expression in hPRL and G129R transgenic mice, respectively, are presented at each time point 
(Table 2.1 and Table 2.2). 
To examine the effect of transgene expression on PRL signaling, approximately 1000 
genes from the literature which have been implicated in PRL signaling were chosen from the 
microarray data and further scrutinized. The changes in this particular set of genes were 
summarized in Table 2.3.  Once again at 24-weeks, the smallest number of genes was 
significantly altered in the transgenic lines, only 10 in all.  The 12- and 36-weeks samples had 48 
and 79 genes significantly altered, respectively.  To compare the effect of systemic expression of 
the two transgenes, the fold change from the hPRL data set was subtracted from the fold change 
of the G129R data set and an average was taken from the 12- and 24-week samples due to the 
lack of a significant phenotypic difference between the two time points.  Genes reported in Table 
2.3 were those that have been altered greater than 2-fold when comparing the hPRL and G129R 
expression.  Several genes, such as Cyclin D1, Bcl2, and Fyn, associated with the PRL-R have 
been significantly altered by the systemic expression of either hPRL or G129R. 
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 Table 2.1  List of the top twelve genes that were altered in expression in the mammary gland of 
hPRL transgenic mice at three different ages. 
.
Age
(weeks) Gene Names GenBank Fold Change
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-21
-21
-23
-24
-26
-26
-34
-37
-42
-119
-147
BG074689
M12233
NM_025288
BC023179
NM_016754
BC025840
AV007306
AJ293626
NM_008508
NM_009405
NM_009394
Mus musculus transcribed sequence
similar to zinc finger protein 113
actin, alpha 1, skeletal muscle
stefin A3
myosin light chain, phosphorylatable, fast skeletal muscle
titin
Mus musculus transcribed sequences
myosin, heavy polypeptide 1, skeletal muscle, adult
Mus musculus transcribed sequence
troponin I, skeletal, fast 2
troponin C2, fast
tropomyosin 3, gamma
SH3-binding domain glutamic acid-rich protein like
-12NM_080435
-21
-13
-13
-13
-14
-14
-15
-16
-16
-16
-16
-34
BF140275
NM_016786
C80828
AK006814
BC009132
AI414399
NM_031389
AF072881
BC013271
NM_022314
NM_019989
NM_013645parvalbumin
adenylate cyclase 4
clathrin, light polypeptide (Lca)
huntingtin interacting protein 2
Mus musculus transcribed sequence
death effector domain-containing
a disintegrin and metalloproteinase domain 15 (metargidin)
ring finger protein 144
ribonuclease/angiogenin inhibitor 2
WD-40-repeat-containing protein with a SOCS box 2
annexin A8
-21
-23
-23
-24
-24
-26
-28
-30
-32
-34
-37
-147
BG064799
NM_022023
AK017072
BB153808
NM_008671
BF159226
BI690209
NM_029562
AF239673
AK013717
AI181686
BC024835
polymerase (DNA directed), gamma
glia maturation factor, beta
tropomodulin 2
dishevelled, dsh homolog 1 (Drosophila)
nucleosome assembly protein 1-like 2
immunoglobulin kappa chain variable 8 (V8)
parvin, alpha
cytochrome P450, family 2, subfamily d, polypeptide 26
v-crk sarcoma virus CT10 oncogene homolog (avian)
tubulin, beta 4
tubulin cofactor a
structure specific recognition protein 1
12
12
14
14
15
16
17
23
37
49
49
111
AK017183
AK007630
AF190152
AV329676
NM_023249
AF333028
NM_020497
AU018166
NM_019914
NM_018887
NM_130796
AK013096
phosphodiesterase 1C
cyclin-dependent kinase inhibitor 1A (P21)
calpastatin
phosphorylase kinase alpha 2
yippee-like 1 (Drosophila)
adrenergic receptor kinase, beta 1
zinc finger protein (C2H2 type) 276
ribosomal protein L41
ALL1-fused gene from chromosome 1q
cytochrome P450, family 39, subfamily a, polypeptide 1
sorting nexin associated golgi protein 1
DNA methyltransferase 3A
18
18
18
20
20
21
21
21
21
23
23
24
24
NM_021485
BB778301
L36316
BI107337
BB320674
BB020556
BC020100
NM_011049
NM_008817
AF065914
AK020845
AF282844
X84237
ribosomal protein S6 kinase, polypeptide 2
neural-salient serine/arginine-rich
zinc finger protein 63
potassium channel, subfamily K, member 5
huntingtin interacting protein 1
inhibitor of growth family, member 3
transmembrane protein 5
PCTAIRE-motif protein kinase 1
paternally expressed 3
interleukin 2
Usher syndrome 2A (autosomal recessive)
matrix metalloproteinase 16
CD3 antigen, zeta polypeptide
32
32
32
34
39
42
45
52
56
69
97
AJ131357
BB204380
NM_031367
NM_011888
NM_013487
AF102134
NM_019992
NM_009844
U95921
M93428
BE686052
chemokine (C-C motif) receptor 9
chemokine (C-C motif) receptor 7
histocompatibility 28
chemokine (C-C motif) ligand 19
CD3 antigen, delta polypeptide
CD22 antigen
BCR downstream signaling 1
CD19 antigen
T-cell receptor alpha chain
glycosylation dependent cell adhesion molecule 1
M.musculus mRNA for esterolytic Ig heavy chain variable region
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 Table 2.2 List of the top twelve genes that were altered in expression in the mammary gland of 
G129R at three different ages 
.
Age
(weeks) GenBank Fold Change
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-12
-12
-14
-14
-15
-17
-17
-23
-26
-64
-119
-119
BF462185
NM_008473
BC025172
BF159226
BB314809
NM_020036
NM_015825
NM_018870
NM_013456
AV007306
NM_008508
NM_025288
-14
-14
-14
-15
-15
-16
-16
-18
-20
-21
-23
-24
AF250838
NM_007932
AU043383
R74734
AF042180
AV216351
AF378762
M33760
AK013520
AF244347
BG071103
AI561743
placental specific protein 1
endoglin
ubiquitin A-52 residue ribosomal protein fusion product 1
inactive X specific transcripts
testis-specific protein, Y-encoded-like
Cd27 binding protein (Hindu God of destruction)
tumor endothelial marker 8 precursor
fibroblast growth factor receptor 1
amyloid beta (A4) precursor protein-binding, family A, member 1 binding protein
ADP-ribosylarginine hydrolase
copine I
cDNA sequence BC004004
-15NM_013601homeo box, msh-like 2
-15
-15
-15
-17
-17
-17
-17
-18
-20
-21
-45
NM_080728
X67685
NM_008250
AA164101
NM_011601
NM_010294
NM_013868
NM_008233
C76677
NM_019660
NM_020033
myosin, heavy polypeptide 7, cardiac muscle, beta
myosin, light polypeptide 3, alkali; ventricular, skeletal, slow
H2.0-like homeo box gene
Mus musculus transcribed sequences
T lymphoma oncogene
glucokinase activity, related sequence 2
heat shock protein family, member 7 (cardiovascular)
hepatoma-derived growth factor, related protein 2
Mus musculus transcribed sequence
c-myc binding protein
ankyrin repeat domain 2 (stretch responsive muscle)
hypothetical protein, I54
keratin complex 2, basic, gene 1
myoglobin
immunoglobulin kappa chain variable 8 (V8)
protocadherin alpha 7
calmodulin 4
SH3-binding domain glutamic acid-rich protein
phosphoglycerate mutase 2
actinin alpha 3
Mus musculus transcribed sequences
Mus musculus transcribed sequence
stefin A3
paired box gene 6
keratin complex 2, basic, gene 8
LIM homeobox protein 3
Mus musculus transcribed sequences
espin
androgen-induced basic leucine zipper
defensin beta 2
activating transcription factor 4
ectodermal-neural cortex 1
complement component 1, q subcomponent binding protein
aquarius
brain protein 17
Mus musculus BIC noncoding mRNA, complete sequence.
rod outer segment membrane protein 1
B-cell CLL/lymphoma 7A
KH domain containing, RNA binding, signal transduction associated 1
coagulation factor X
serine (or cysteine) proteinase inhibitor, clade I, member 1
Mus musculus, Similar to KIAA0513 gene product
casein delta
acyl-Coenzyme A oxidase 2, branched chain
cytochrome P450, family 3, subfamily a, polypeptide 41
germ cell-specific ankyrin
whey acidic protein
12
12
13
13
14
14
14
14
14
15
16
45
20
20
20
23
23
24
24
24
24
37
45
49
BF456245
AW322280
L38248
BG066800
NM_019585
BC022605
NM_010030
M94087
BM120053
NM_007573
BE573695
BC008274
13
13
13
13
14
15
16
17
20
26
32
37
AY096003
NM_009073
BC017640
BB752997
AI506285
BC006776
BC016247
NM_009973
NM_053115
NM_017396
AF459789
NM_011709
NM_017399
AK017818
BB204380
AW741731
T25656
BF303285
NM_009639
AA267307
NM_027832
U95921
M93428
BE686052
fatty acid binding protein 1, liver
Ras-related GTP binding D
chemokine (C-C motif) receptor 7
protein phosphatase 2, regulatory subunit B (B56), alpha isoform
Mus musculus transcribed sequence
Tcfcp2-related transcriptional repressor 1
acidic epididymal glycoprotein 2
Mus musculus transcribed sequences
seminal vesicle antigen-like 1
T-cell receptor alpha chain
glycosylation dependent cell adhesion molecule 1
M.musculus mRNA for esterolytic Ig heavy chain variable region
g g
Gene Names
G
12
9R
 U
p-
R
eg
ul
at
ed
 G
en
es
G
12
9R
 D
ow
n-
R
eg
ul
at
ed
 G
en
es
 67
 Table 2.3.  List of the top twelve PRL genes that were altered in expression in the mammary 
gland contrasting the pattern of expression between hPRL and G129R transgenic mice at three 
different ages.  
. 
Age
(weeks) GenBank Fold Change
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M92420
AB021226
BB370469
NM_134144
NM_010810
NM_010086
NM_009028
NM_009613
NM_011245
BB271919
NM_010003
NM_007785
transforming growth factor alpha
matrix metalloproteinase 24
mitogen activated protein kinase kinase kinase 12
cytochrome P450, family 2, subfamily c, polypeptide 50
matrix metalloproteinase 7
a disintegrin and metalloprotease domain 24 (testase 1)
RAS-like, family 2, locus 9
a disintegrin and metalloprotease domain 11
RAS protein-specific guanine nucleotide-releasing factor 1
Ras-like without CAAX 2
cytochrome P450, family 2, subfamily c, polypeptide 39
casein gamma
4
BF660388
BB667491
BB538325
AK010939
U04710
AK014988
NM_054098
BM248342
BF142527
AK007630
BB703307
NM_018887
protein kinase C, beta
Cdk5 and Abl enzyme substrate 2
cyclin D1
heat shock factor binding protein 1
insulin-like growth factor 2 receptor
suppressor of cytokine signaling 7
Tnfa-induced adipose-related protein
transforming growth factor, beta receptor I
RAS related protein 1b
cyclin-dependent kinase inhibitor 1A (P21)
Ras association (RalGDS/AF-6) domain family 3
cytochrome P450, family 39, subfamily a, polypeptide 1
4
4
4
4
5
6
7
9
10
13
49
AF201285
AF128849
BF142527
AV309800
AA068868
NM_008054
BC011511
AW541674
NM_009613
AF282844
NM_019660
NM_013868
transforming growth factor beta 1 induced transcript 4
cytochrome P450, family 2, subfamily b, polypeptide 20
RAS related protein 1b
poly(rC) binding protein 2
cyclin H
Fyn proto-oncogene
Ras association (RalGDS/AF-6) domain family 3
mitogen activated protein kinase kinase 7
a disintegrin and metalloprotease domain 11
matrix metalloproteinase 16
c-myc binding protein
heat shock protein family, member 7 (cardiovascular)
8
9
9
11
12
13
15
16
21
21
24
30
NM_010084
NM_011611
NM_019418
NM_013766
AA543265
NM_011369
AF128849
BG065298
NM_009403
NM_011487
AU015121
NM_024444
a disintegrin and metalloprotease domain 18
tumor necrosis factor receptor superfamily, member 5
tumor necrosis factor (ligand) superfamily, member 14
prolactin-like protein I
heat shock protein, A
Shc SH2-domain binding protein 1
cytochrome P450, family 2, subfamily b, polypeptide 20
Son of sevenless homolog 1 (Drosophila)
tumor necrosis factor (ligand) superfamily, member 8
signal transducer and activator of transcription 4
cyclin B1
cytochrome P450, family 4, subfamily f, polypeptide 18
6
6
6
6
6
6
6
7
9
9
11
11
NM_009943
NM_007402
D67017
AK006814
BC018472
BM198314
NM_007788
AW763765
AV023206
M94087
NM_007788
NM_029562
D67017
cytochrome c oxidase, subunit VI a, polypeptide 2
a disintegrin and metalloprotease domain 7
heat shock protein 105
death effector domain-containing
dopamine responsive protein
KDEL containing protein 1
casein kinase II, alpha 1 related sequence 4
heat shock protein 1A
cytochrome c oxidase, subunit Vb
activating transcription factor 4
casein kinase II, alpha 1 related sequence 4
cytochrome P450, family 2, subfamily d, polypeptide 26
heat shock protein 105
-8
-9
-9
-9
-10
-10
-11
-12
-12
-15
-20
-39
-6
BI154147
AV113827
NM_023670
AV023206
BC009132
BB667338
NM_009973
AK006814
NM_017396
AK013255
NM_019989
heat shock protein 1, beta
ankyrin repeat and SOCS box-containing protein 4
insulin-like growth factor 2, binding protein 3
cytochrome c oxidase, subunit Vb
a disintegrin and metalloproteinase domain 15 (metargidin)
cytochrome P450, family 7, subfamily a, polypeptide 1
casein delta
death effector domain-containing
cytochrome P450, family 3, subfamily a, polypeptide 41
cell division cycle 37 homolog (S. cerevisiae)
SH3-binding domain glutamic acid-rich protein like
-7
-7
-10
-11
-11
-11
-12
-13
-23
-24
-37
-5
-5
-5
-5
-6
-6
-6
-6
-7
-8
-9
-10
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 2.5 Discussion 
While genetic manipulation of cells in vitro proves to be an effective means of studying 
the gene function, the use of transgenic mice provides a more comprehensive understanding of 
the relevance of the particular gene product on a complete physiological platform (Auerbach 
2004).   In this study the antagonistic effects of G129R in mammary gland development and its 
potential role in cancer prevention have been confirmed.  This was accomplished by using 
transgenic mice expressing concentrations of hPRL equalivant to that of normal mice (non-
lactating or non-pregnant) or similar amounts of hPRL’s antagonist, G129R.  The whole mount 
images of the mammary glands from virgin female G129R mice revealed that the ductal network 
and lack of end bud development was similar to that of PRL or PRLR gene knockouts 
(Vomachka, Pratt et al. 2000; Saunier, Dif et al. 2003).  The presence of the slender, tapering, 
and blunt ended terminal buds at 12- and 36-weeks confirmed that prolonged expression of low 
levels (5 to 10 ng/mL) of G129R effectively blocks ability of endogenous PRL to stimulate alveolar 
bud formation within the mammary gland.  The observations made in the 36-week whole mount 
also imply that the systemic expression of hPRL at these low levels has an anti-aging effect on 
the mammary gland.  The non-transgenic mice were observed to have a decrease in budding and 
the G129R mice were severely impaired, while the hPRL mice still showed a substantial degree 
of budding throughout the gland. 
The antagonistic nature of G129R was able to block the effect of endogenous hormonal 
stimulation in the mammary gland as presented in Figure 2.2 as whole mounts.  This inhibitory 
effect of G129R translated to a resistance to the carcinogen induced breast tumorigenesis.  The 
decrease of tumor formation in DMBA treated G129R transgenic mice suggests the potential role 
of using anti-PRL agent such as PRLR antagonist in mammary tumor prevention.  While the 
therapeutic potential of G129R has been previously reported using T47D and MCF-7 cell 
xenograft models (Chen, Holle et al. 2002) the data presented here demonstrated the ability of 
prolonged, low dose exposure G129R to protect the mammary gland from the tumor initiation 
process by a potent chemical carcinogen. When viewing PRL acting as a survival factor enabling 
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 cancer cells to evade apoptosis (Perks, Keith et al. 2004), it becomes clear in this model that 
G129R is blocking the survival of cancerous cells.  Although there is no difference in the tumor 
rates between the PRL transgenics and the non-transgenic controls after DMBA treatment, the 
tumor appearance time is significantly changed, i.e.  it takes only 20 weeks for 40% of hPRL 
transgenic mice to develop tumor as compare to 26 week in control mice.    This result implied the 
role of PRL in DMBA initiated breast tumorigenesis.   
The high mortality rates in DMBA treated groups may be due to the fact that DMBA has 
been shown to induce cancers in other organs (Das, Delp et al. 1989; Izzotti, Camoirano et al. 
1999; Granberg, Brunstrom et al. 2000; Lindhe, Granberg et al. 2002), although we did not find 
obvious tumor mass in the deceased mice.  Prior investigation using tritiated-hydrogen-labeled 
DMBA to treat rodents has revealed DMBA-DNA adduct formation in the heart, lung, liver, 
mammary gland, and adrenal gland.  The lower mortality rate observed in the G129R transgenic 
line maybe due to the fact that Mt-G129R transgenic mice express G129R in the majority of the 
organs.  The results infer that the general expression pattern of a pro-apoptosis agent decreased 
the susceptibility of the cells to DMBA, which make them less vulnerable to the environmental 
carcinogen insult. 
PRL exerts its major physiological effects during three stages of the mammary gland 
development (Horseman 1999):  lobular budding during organogenesis, lobuloalveolar 
development in early pregnancy, and differentiation and control of milk secretion during lactation.  
During these times there is a large increase in the secretion of PRL from the pituitary gland 
resulting in a dramatic alteration in gene expression as well as phenotypic alterations (Felig and 
Frohman 2001).  In the model presented here, the effect of prolonged systemic expression of 
hPRL or its antagonist at relatively low concentrations resulted in drastic phenotypic differences 
within the mammary gland.  However, similar alterations in gene expression were not as obvious.  
One explanation is that transgenic mice may have adapted to the constant presence of hPRL and 
G129R in their system.  The phenotypic alteration caused by expression of hPRL and G129R are 
most likely a function of the accumulation of small changes in the expression of the genes 
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 involved in the signaling pathways and reflects changes in the activation states of the proteins 
involved in these pathways. 
Using cDNA microarray we reported the gene expression pattern that was altered in 
different transgenics animal at different development stages (Tables 2.1- 2.3).  While PRL was 
given its name due to its involvement in growth and lactation of mammary gland cells, the protein 
also has a wide variety of other biological activities. These activities range from osmoregulation to 
angiogenesis to intersystem communication (Freeman, Kanyicska et al. 2000). These functions 
are elicited through a complex signaling cascade in which the intracellular domain of the PRLR 
plays a vital role (Bole-Feysot, Goffin et al. 1998).  Activation of the Jak/Stat pathway is 
considered the most important pathway initiated by the activation of the hPRLR, the 
phosphorylated tyrosine residues can also serve as docking sites for adapter proteins, Shc, Grb2, 
and Sos, which connect the receptor to the Ras/Raf/MAP kinase cascade.  This pathway also 
involves activation of transcription cofactors within the nucleus (Das and Vonderhaar 1996).  
Activation of these molecules results in further stimulation of proliferation.  As shown in Table 2.3, 
several Ras related proteins are up-regulated in the hPRL transgenic animals, as is the Fyn 
proto-oncogen.  The role of PRL in regulating the expression of a variety of cell-cycle-related 
transcripts was also confirmed in the animal models used in this study.  Cyclin D1 expression has 
been shown to increase in the presence of PRL in vitro (Brockman, Schroeder et al. 2002; 
Schroeder, Symowicz et al. 2002).  It has also been demonstrated that IGF-2 is a mediator of 
prolactin-induced morphogenesis and cyclin D1 expression (Brisken, Ayyannan et al. 2002).  The 
expression of cyclin D1 is up-regulated, in the hPRL transgenic lines, as seen in Table 2.3.  It 
should also be noted that IGF-2 is up-regulated in the hPRL transgenic line, while be it only 
slightly.  Cyclin B1 has also been shown to be up-regulated in the presence of PRL in vitro (33) 
and is up-regulated in the hPRL transgenic line (Table 2.3).  The data presented also imply the 
possible connection between PRL and several other classes of proteins, such as, adhesion 
molecules (Glycam1, 36) and heat shock proteins (Blake, Buckley et al. 1995; Zhang, Blake et al. 
1999).  
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 In summary, the systemic expression of low levels of hPRL or G129R exhibited a 
significant impact on the development of the mammary gland during the lifespan of the mouse.  
The constant presence of hPRL leads to an abnormal increase in the budding within the gland, 
while expression of G129R inhibited the mammary gland development demonstrated by slender, 
tapering, and blunt-ended terminal buds similar to those of PRLR or PRL gene knock out mice.  
The presence of G129R, even at the very low concentration, in the transgenic mice was sufficient 
to provide a significant protective measure to the DMBA initiated breast tumorigenesis suggesting 
the potential role of G129R as a chemopreventive agent in breast cancer. 
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COMBINATION THERAPY USING THREE NOVEL PROLACTIN RECEPTOR ANTAGONIST 
BASED FUSION PROTEINS EFFECTIVELY INHIBITS TUMOR RECURRENCE  
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 3.1 Abstract 
Previously, prolactin receptor antagonist (G129R) based fusion proteins were developed 
including fusions with an angiogenesis inhibitor (endostatin), an immune system modulator 
(interleukin 2), and a cytotoxin (PE38KDEL).  Each fusion protein was designed to target the 
mammary gland via the G129R moiety and at the same time attack a hallmark common to tumor 
cells via the second moiety.  To test the feasibility and to optimize a treatment regimen, 
xenografts of a mammary carcinoma cell line (McNeuA) derived from an MMTV-neu transgenic 
mouse were used.  Growth of the xenografts was significantly retarded by both regimens which 
combined all three fusion proteins.  In addition, a significant increase in cytotoxic CD8+ T cells 
was observed within the tumors of the combination treated groups.  After establishing the dosing 
regimen, two doses of cocktail treatment (low and high doses administered twice weekly) along 
with individual component controls were administered to female MMTV-neu transgenic mice after 
surgical removal of a natural occurring tumor.  The average tumor recurrence time was 
significantly delayed in both low and high combination treatment groups in comparison to the no 
treatment control group (34 days, 50 days and 18 days, respectively).  The total numbers of lung 
metastases were also significantly decreased in both combination treatment groups.  In 
conclusion, using G129R to target mammary tissue and to tackle multiple hallmarks of cancer at 
the same time with these fusion proteins is an effective strategy for treating the aggressive 
MMTV-neu mouse tumor model. 
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 3.2 Introduction 
Hormones that are intimately involved in normal mammary gland development such as 
estrogens, EGF and PRL strongly influence the initiation and/or progression of breast cancer.  
Hormonal imbalances are a major risk factor for developing breast cancer.  Studies have shown 
that PRL is expressed in the epithelium of human breast cancers and that PRLR levels are higher 
in a majority of benign and malignant tumors than the surrounding and normal mammary tissue 
(Reynolds, Montone et al. 1997; Touraine, Martini et al. 1998).  In addition, PRL and the PRLR 
appear to have a role in both hormone responsive and hormone-independent breast cancers.  
PRL interacts synergistically with estrogen and progesterone to promote cancerous growth since 
the receptors for these ligands are often co-expressed in primary breast cancers (Ormandy, Hall 
et al. 1997).  Furthermore, PRL has been shown to be able to transactivate HER-2 through the 
activation of JAK2 (Yamauchi, Yamauchi et al. 2000; Scotti, Langenheim et al. 2007).  In 
accordance, the anti-proliferative effects of Tamoxifen (Chen, Ramamoorthy et al. 1999) or 
Herceptin (Ropero, Menendez et al. 2004) in T-47D cells were enhanced when combined with a 
PRLR antagonist.   
Approximately 50% of breast cancers are hormone-independent and do not respond to 
Tamoxifen therapy.  Similarly, over-expression of HER2 occurs only in less than 30% of breast 
cancer patients (Slamon, Godolphin et al. 1989) and is associated with resistance to conventional 
chemotherapy (Wright, Cairns et al. 1992).  Deregulation of HER2 results in an aggressive 
phenotype and is associated with a poor prognosis, a decrease in disease-free survival, and an 
increase in metastasis (Layfield, Glasgow et al. 1989; Green, Dowley et al. 1995).  Breast 
cancers overexpressing HER2 have been reported to have a higher proliferative activity in the 
presence of PRL and to have increased metastatic activity (Yamauchi, Yamauchi et al. 2000).  
The prevalence of PRL signaling in both hormone responsive and hormone-independent breast 
cancers makes the PRLR an appealing target for development of broad spectrum breast cancer 
therapeutics. 
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 A PRLR antagonist, G129R, with similar affinity as human (h) PRL for the receptor was 
developed by substituting a glycine residue at position 129 of hPRL with an arginine residue 
(Goffin and Kelly 1996; Chen, Ramamoorthy et al. 1999).  It has been demonstrated that G129R 
inhibits cell proliferation in human breast cancer cell lines in a dose dependent manner (Chen, 
Ramamoorthy et al. 1999), competitively blocks hPRL-induced Jak/STAT, Ras/Raf/MAPK, and 
PI3K/Akt signal transduction, up-regulates a tumor suppressor (TGF-β), down-regulates a proto-
oncogene (bcl-2), leading to the arrest of cell cycle progression and in some circumstances the 
induction of apoptosis (Cataldo, Chen et al. 2000; Beck, Peirce et al. 2002; Peirce and Chen 
2004).   
In an effort to generate mammary tissue-targeting therapeutics, several dual-function 
fusion proteins were generated which combined G129R with an angiogenesis inhibitor, G129R-
Endostatin (Beck, Chen et al. 2003); an immune system modulator, G129R-IL2 (Zhang, Li et al. 
2002); or a cytotoxin, G129R-PE38KDEL (Langenheim and Chen 2005).  The G129R moieties of 
the fusions retain the ability to bind to the PRLR and competitively block hPRL-induced signal 
transduction.  The functions of the second moiety in each of these fusion proteins were also 
confirmed.  G129R-Endostatin was as effective as endostatin alone at inhibiting tube formation 
and proliferation of HUVEC cells (Beck, Chen et al. 2003).  G129R-IL2 was able to stimulate the 
proliferation of CTLL2 cells as effectively as IL2 (Zhang, Li et al. 2002).  G129R-PE38KDEL 
showed specificity towards breast cancer cells expressing the PRLR, inhibited protein synthesis 
and caused cell death (Langenheim and Chen 2005).  Finally, all three fusion proteins were able 
to slow the growth of T-47D xenografts in nude mice as a monotherapy (Zhang, Li et al. 2002; 
Beck, Chen et al. 2003; Langenheim and Chen 2005). 
Conventional chemotherapy has employed small molecules that target DNA synthesis 
and replication activities including alklating agents, anti-metabolites, plant alkloids, and 
topoisomerase inhibitors.  Although these agents were designed to kill rapidly dividing cancer 
cells, they often damage many others, thereby creating significant side effects.  The use of these 
agents in combination in order to reduce the dose needed and also improve the therapeutic 
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 outcome represents the current tread, but are still only focusing on one aspect of cancer cell 
physiology, DNA replication.  Recent efforts have been shifted to develop novel therapeutic 
agents targeting unique biomarkers of the cancer cells themselves such as exploiting overly 
expressed receptors (such as HER2/neu), tumor oncogenes (such as Bcr-Abl), or the angiogenic 
needs of tumors (such as VEGFR/VEGF) (Harari 2004; Pal and Pegram 2007; Thatcher 2007).  
Also, the use of these strategies in combination is under investigation.  For example, the use of 
Herceptin along with paclitaxel, cisplatin, or radiation has been shown to increase the survival 
rate by up to 50% (Safran, Dipetrillo et al. 2007).  The small molecule Bcr-Abl inhibitor, imatinib 
mesylate, has been shown to sensitize cancer cells to radiation treatment (Quick and Gewirtz 
2006).  The use of a monoclonal antibody specific for the EGFR, cetuximab, and a small 
molecular inhibitor of the EGFR, gefitinib, in combination show a shared complementary mode of 
action and a synergistic response in vivo (Huang, Armstrong et al. 2004; Matar, Rojo et al. 2004). 
These combinations represent the future of cancer therapy that is designed to target the multiple 
hallmarks of cancer. 
In the present study, the effectiveness of using the three fusion proteins in combination 
for treating aggressive subtypes of mammary carcinomas was tested in a more clinically relevant 
mouse tumor model.  A highly significant and dose dependent delay in tumor recurrence and 
reduction in lung metastasis were observed in mice treated with the fusion protein combinations. 
3.3 Material and Methods 
3.3.1 Protein Production 
The pET22b(+) based plasmids containing cDNAs encoding G129R-PE38KDEL, G129R-
IL2 or G129R-Endostatin were transformed into Rossetta (DE3)pLysS competent E. coli cells 
(Novagen/EMD Biosciences, San Diego, CA).  Protein expression, isolation of inclusion bodies, 
refolding and purification protocols were reported previously (Chen, Ramamoorthy et al. 1999; 
Beck, Chen et al. 2003).  Briefly, Rossetta (Novagen) chemically competent cells were 
transformed with pET22b(+) vector encoding for G129R-(G3S)4-PE38-KDEL, G129R-IL2 and 
G129R-Endostatin cDNA. Bacteria were inoculated in Luria-Bertani broth (ampicillin, 50 µg/ml) at 
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 37°C, and induced with isopropyl-beta-D-thiogalactopyranoside (IPTG) for 3 h to protein 
expression. Bacteria were collected and were resuspended buffer A [5.0M Na2HPO4, 5 mM 
EDTA, 0.5% Triton X-100], followed by incubation for 1 h with the addition of lysozyme at a final 
concentration of 25 µg/ml. The suspension was then sonicated using a 550 Sonic Dismembrator 
(Fisher Scientific, Pittsburgh, PA) followed by centrifugation at 8000 x g for 10 min. The pellet was 
resuspended buffer A containing 1M Urea. The centrifugation/resuspension procedure was 
repeated twice. The pellet was dissolved in 30 ml of buffer B [0.05 M Tris (pH 8.0), 0.5% SDS, 
and 1 mM DTT] and was centrifuged at 8000 x g for 10 min at 4°C. The clear supernatant 
obtained was then transferred to dialysis tubing with a Mr cutoff of 10,000 and was dialyzed twice 
in 1500 ml of buffer C [0.05 M Tris-HCl (pH 8.0) and 0.1 mM DTT] at 4°C for 4 h. The recombinant 
protein was then further dialyzed twice in 1500 ml of buffer D [0.05 M Tris-HCl (pH 8.0)] and twice 
in 1000 ml of buffer E [0.05 M Tris-HCl (pH 8.0), 0.01 mM oxidized glutathione, and 1 mM 
reduced glutathione] at 4°C for 4 h/dialysis cycle, respectively. A final dialysis in 0.05 M Tris-HCl 
(pH 8.0) was performed overnight. 
The function of both moieties of each fusion protein was determined as described 
previously (Zhang, Li et al. 2002; Beck, Chen et al. 2003; Langenheim and Chen 2005).  Briefly, 
the human breast ductal carcinoma cell line T-47D was purchased from the American Type 
Culture Collection (Manassas, VA) and was maintained in RPMI 1640 medium supplemented 
with 10% (v/v) fetal bovine serum and 10 µg/ml gentamicin. The cell line was maintained at 37°C 
in a humidified atmosphere in the presence of 5% CO2. Treatment of the cells was performed at 
37°C in serum-free medium. Experiments were terminated by washing the cells with ice-cold 
phosphate buffered saline (PBS) supplemented with 0.4 mM sodium orthovanadate and 
resuspending them in lysis buffer (50 mM Tris-HCl, pH 8.0; 150 mM NaCl; 1% (v/v) NP-40) 
supplemented with protease inhibitors (100 mM sodium fluoride; 2 mM EDTA; 1 mM 
phenylmethylsulfonyl fluoride; 1 mM sodium orthovanadate; 5 µg/ml aprotinin; 5 µg/ml leupeptin). 
Cell lysates were harvested into eppendorf tubes, placed on ice for 15 min and centrifuged at 
15,000 g for 15 min at 4°C. Supernatants were collected and the protein content was determined 
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 using Coomassie Plus Protein Assay Reagent and BSA standards (Peirce Biotechnology, 
Rockford, IL). For immunoblots, cell lysates (50 µg) were separated on 10% polyacrylamide gels 
by reducing SDS-PAGE (Bio-Rad, Hercules, CA) and immunoblotted.  The following 
concentrations of primary antibodies were used: 1:1,000 dilution of anti-phospho-STAT5a/b 
(Upstate, Charlottesville, VA) and anti-STAT5 (Santa Cruz Biotechnology) diluted to 1:1,000. The 
secondary antibodies, goat anti-mouse or goat anti-rabbit IgG-horseradish peroxidase-conjugates 
were obtained from Bio-Rad Laboratories and used at a dilution of 1:2000.  
To improve the yield of G129R-IL2, an unpaired cysteine at position 125 of IL2 was 
substituted with an alanine.  This substitution mutation does not affect the function of IL2 (Boone, 
Chazin et al. 1988).  To enhance the cytotoxicity of the exotoxin, domain 1a of the toxin moiety 
was removed to create G129R-PE38KDEL (Kreitman, Siegall et al. 1992).  
3.3.2 Transgenic Mice 
Breeding pairs of FVB/N-Tg(MMTVneu)202Mul/J (Muller, Arteaga et al. 1996) mice were 
obtained from Jackson Laboratory (Jackson Laboratory, Bar Harbor, Maine).  The colony was 
expanded and housed in accordance with The Guide for the Care and Use of Laboratory 
Animals.  To implant xenografts or remove tumors, mice were anesthetized with 0.4 mg/g body 
weight of 2,2,2-tribromethanol (Sigma-Aldrich, St Louis, MO) prepared in tert-amyl alcohol 
(Sigma-Aldrich) and saline.   
3.3.3 RT-PCR  
To confirm expression of mouse PRLR, mammary gland or tumor tissue of MMTV-neu 
transgenic mice were dissected and frozen until time of use.  Approximately 50-100 mg of frozen 
tissue was homogenized in 1 mL Trizol (Invitrogen; Carlsbad, CA) on ice using a motorized 
homogenizer and processed according to the manufacturer’s instructions to isolate RNA.  RT-
PCR was performed with the Access Quick RT-PCR system (Promega, Madison, WI) using the 
following conditions: 45 min at 48°C; 1 min at 94°C; 25 cycles: 30 sec at 94°C, 1 min at 62°C, 1 
min at 72°C; 6 min at 72°C; and a final hold at 4°C.  Primers used for mouse PRLR were 5’-
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 GGCCCCAATTCCTGTTTCTTTAGC-3’ and 5’GCCACTGCCCAGACCATAATCAAAC-3’; primers 
for glyceraldehyde-3-phosphate dehydrogenase (G3PDH) were 5’-ACCACAGTCCATGCC 
ATCAC-3’ and 5’-TCCACCACCCTGTTGCTGTA-3’. 
3.3.4 Apoptosis Assay 
MCNeuA cells were kindly provided by Dr. Michael Campbell, and cultured as previously 
described (Campbell, Wollish et al. 2002).  For the apoptosis assay, cells were seeded in twelve-
well plates at a concentration of 1.5x105
 
cells per well in DMEM containing 10% CSS and allowed 
to adhere overnight. Treatments were made in DMEM containing 0.5% CSS.  A naive control with 
only media and a positive control with 0.5 µM strautasporine were utilized.  G129R was 
administered at 3000 ng/mL, while each fusion protein was administered at 150, 500, and 1500 
ng/mL.  Each sample was prepared in triplicate.  After 72 hours the non-adherent apoptotic cells 
in the medium and the viable adherent cells from each individual well were collected and 
transferred into 1.5 ml tubes and centrifuged at 340 x g for 7 min at 4°C. The pellets were re-
suspended in approximately 100 μl of growth media and kept on ice. The re-suspended cells 
were diluted 1:10 to 1:20 in Guava® ViaCount® Reagent (Guava Technologies, Hayward, CA) 
which contains two DNA-binding dyes, one of which selectively penetrates apoptotic and dead 
cells characterized by compromised membrane integrity and one which penetrates all nucleated 
cells. Following the five minute incubation, the stained cells were analyzed on a Guava Personal 
Cytometer (Guava Technologies). Each sample was analyzed using Guava CytoAnalysis 
software (Guava Technologies). The ratio of live/healthy cells, apoptotic cells and dead cells were 
expressed as a percentage of the total cellular population for each sample. Data are expressed 
as mean ± SEM and are representative of three experiments.  
3.3.5 McNeuA Xenograft Experiment 
At time of implantation, cells were trypsinized, washed with growth medium, counted and 
re-suspended at a concentration of 3x106 cells/0.1 mL in PBS.  The mixture was diluted 1:1 (v/v) 
with Matrigel (BD Biosciences, Franklin Lakes, NJ) and injected into the anterior fat pad of 3 
month old homozygous MMTV-neu virgin female mouse (0.2 ml/mouse).  Mice were randomly 
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 sorted into 9 groups of 4 mice and treatments with the fusion proteins were initiated three days 
after implantation. 
Mice were intraperitoneally (i.p.) administered a low dose of each fusion protein 
individually (50 µg G129R-Endostatin, 50 µg G129R-IL2, or 10 µg G129R-PE38KDEL), a high 
dose of each fusion protein individually (100 µg G129R-Endostatin, 100 µg G129R-IL2, or 25 µg 
G129R-PE38KDEL), the combination of the low doses, the combination of the high doses, or 
PBS.  All dosages were adjusted to a single 0.2 mL injection volume.  Dosages were determined 
from previous published data on each fusion protein.  These dosages were non-lethal and 
showed ample difference in growth of T47D xenografts in nude mice.  Treatments were 
administered every three days for 27 days.  The short (S) and long (L) axies of the tumors were 
measured and the tumor volume (V) was calculated using the formula for a spheroid (V = 4/3π x 
L/2 x S/2 x S/2).  On day 28 of the experiment, tumors were dissected and split into thirds: one 
part for fixation in formalin, one part for flow cytometry and one part for cryopreservation.  
Spleens were removed for flow cytometry.  Lungs were removed and placed in Bouin’s Fixative 
(Sigma-Aldrich) to stain.  The presence or absence of macrometastases was recorded and the 
Chi-squared test of independence was used to determine significance between treatment groups. 
3.3.6 MMTV-neu Transgenic Mouse Mammary Tumor Surgical Model 
Due to natural variation in tumor formation rates, mammary tumors from 6 to 10 MMTV-
neu mice were removed in intervals based upon similarity in tumor size.  Healthy mice showing 
no ill effects from the surgery were randomized into control and treatment groups.  The day after 
surgery, mice were started on a twice weekly low dose combination regimen (100 µg G129R-
Endostatin, 100 µg G129R-IL2, and 20 µg G129R-PE38KDEL), high dose combination regimen 
(200 µg G129R-Endostatin, 200 µg G129R-IL2, and 25 µg G129R-PE38KDEL), 200 µg G129R 5 
days per week or PBS.  Animals were palpitated at time of injections and tumor recurrence was 
noted; treatments were ceased after recurrent tumors reached approximately 1 cm in diameter at 
which point animals were sacrificed and handled as described above. 
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 3.3.7 Flow Cytometry 
Single cell suspensions were obtained from the isolated spleens and tumor fractions.  
The tumor single cell suspensions were enriched for tumor-infiltrating lymphocytes by Percoll 
(Sigma-Aldrich) density gradient centrifugation.  Tumor-infiltrating lymphocytes were collected at 
the 1.055-1.07 g/ml interface and washed three times with PBS.  As per guidelines from Guava 
Technologies (Hayward, CA), cells were incubated with 5 µg/ml of antibodies directed against 
CD3 and CD4 or CD3 and CD8.  All antibodies were obtained in conjugated form from BD 
Bioscience (San Jose, CA). 
3.3.8 Immunohistochemistry 
 Formalin fixed tumors were paraffin embedded, cut into 5 µm sections and placed on 
glass slides. The sections were deparaffinized in xylene and rehydrated in a graded series of 
ethanol.  The sections were initially covered with hematoxylin for 10 to 60 seconds and washed 
with water.  The sections were then covered by eosin for 60 seconds, washed with water and 
dehydrated with ethanol.  The slides were placed in xylene before securing a cover slip.  For 
antigen retrieval, deparaffinized and rehydrated slides were submerged in high pH antigen 
retrieval solution (Biocare Medical, Concord, CA), placed under pressure in a decloaking 
chamber (Biocare Medical) and washed with distilled water.  Slides were blocked for 10 minutes 
and incubated with CD4 (BC/1F6, Biocare Medical) or CD31 (MEC13.3, Biocare Medical) for 60 
and 45 minutes, respectively, followed by incubation in Evision+ Dual Link HRP detection Kit 
(Dako, Carpinteria, CA) for 30 minutes.  Anitbody/enzyme complex was visualized with DAB 
(Biocare Medical) for 3 minutes and counterstained with hematoxylin for 5 minutes. 
3.4 Results 
3.4.1 PRLR Expression Levels in Normal or Malignant Mammary Tissue of MMTV-neu Mice 
and the Response of McNeuA Cells to the Fusion Proteins in vitro 
The mouse PRLR expression levels in the tumors and normal mammary gland of the 
MMTV-neu mice were compared by RT-PCR.  As shown in Figures 3.1 and 3.2, the expression 
levels of mouse PRLR in the tumors were significantly increased (P<0.05) as compared to that of 
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 adjacent normal mammary gland, providing a rationale for targeted treatment with the PRLR 
antagonist based fusion proteins.  The effect of G129R on MCNeuA cells was determined as 
shown in Figure 3.3.  McNeuA cells exhibit resistance to 3000 ng/mL G129R shown here and in 
data not shown are unresponsive to dosages up to 10 µg/mL.  However, the G129R-PE38KDEL, 
as expected, does show the ability to induce apoptosis in MCNeuA cells.  The 1500 ng/mL 
G129R-PE38KDEL fusion protein treatment was the only treatment which significantly decreased 
the percent of viable cells after 48 hour treatment.  
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Figure 3.1.  PRLR in Surgical and Xenograft Model.  The expression of PRLR was 
confirmed in the mammary gland and tumors by RT-PCR with primer specific to mouse PRLR.  
The mammary tumors and its adjacent normal mammary gland tissue from 9 month old female 
mice (n=4) were compared. The PCR products were resolved by electrophoresis in 1% agarose 
gels.  In data not shown, the reactions were run without reverse transcriptase to confirm the 
absence of DNA in each sample. 
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Figure 3.2.  Analysis of PRLR in Surgical and Xenograft Model.  Gel electrophoresis 
photography was analyzed with the Kodak 1D Image Analysis software to compare the 
mean intensity of the bands from Figure 3.1.  The ratio of PRLR to G3PDH was compared 
in each sample.  The average and STD for each group, depicted above revealed a 
statistical difference was observed between the mammary gland and tumor tissue 
(*P<0.02).  
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Figure 3.3.  McNeuA cell apoptosis assay.  McNeuA cells were cultured in the presence of 
G129R (3000 ng/mL), 0.5 µM strautasporine, or each of the fusion proteins at 150, 500, 
and 1500 ng/mL for 72 hours.  The numbers of live/healthy cells were expressed as a 
percentage of the total cellular population for each sample. Data are expressed as mean ± 
SEM and are representative of three experiments (*P<0.001).  There is a significant 
difference observed in the high doses of the G129R-Endostatin and G129R-PE38KDEL 
fusion protein treatment, along with the strautasporine control relative to the naive control.   
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 3.4.2 MCNeuA Xenograft Studies 
The tumor growth rate of all treatment groups was retarded by day 24 of the study as 
compared to that of the PBS controls (Figures 3.4, low dose; and 3.5, high dose).  As show in 
Figure 3.4, a significant difference in the tumor volumes was observed for both G129R-
PE38KDEL alone and the combination (P<0.001 in both cases).  While a decrease in tumor 
volume is observed in the G129R-IL2 and G129R-Endostatin treatment groups, these differences 
were not significant.  In the high dose treatments groups there was also a significant reduction in 
tumor volume in the G129R-PE38KDEL and combination treatment groups (P<0.001 in both 
cases).  No significant difference in tumor volume was observed between the groups receiving 
low or high dose combination treatments.  
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Figure 3.4:  Low Dose MCNeuA Cell Xenograft Studies.  After tumor cell inoculation, two 
dosages of each fusion protein and two doses of combination were used to evaluate 
efficacy.  Treatments administered consisted of G129R-Endostatin (50 ug), G129R-IL2 (50 
ug) and G129R-PE38KDEL (10 ug) and the low dose combination.  The specified amount 
of each fusion protein was placed into the mouse via a single injection.  All treatments were 
diluted in 0.2 mL PBS and injected i.p. into the mouse at the specified interval. Tumor 
volumes were calculated at each treatment time point throughout the study.  A significant 
decrease in tumor volume was observed in the final two measurements of the both 
individual toxin dosages as well as both combination treatments as compared to the PBS 
control (P< 0.001 in all cases).   
 
 88
  
 
 
Figure 3.5:  High Dose MCNeuA Cell Xenograft Studies.  After tumor cell inoculation, two 
dosages of each fusion protein and two doses of combination were used to evaluate 
efficacy.  Treatments administered consisted of G129R-Endostatin (100 ug), G129R-IL2 
(100 ug) and G129R-PE38KDEL (25 ug) and the high dose combination.  The specified 
amount of each fusion protein was placed into the mouse via a single injection.  All 
treatments were diluted in 0.2 mL PBS and injected i.p. into the mouse at the specified 
interval. Tumor volumes were calculated at each treatment time point throughout the study.  
A significant decrease in tumor volume was observed in the final two measurements of the 
both individual toxin dosages as well as both combination treatments as compared to the 
PBS control (P< 0.001 in all cases).   
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 To examine the second moiety function of G129R-IL2, as well as determine any signs of 
global toxicity, spleenic cellularity and tumor infiltrating lymphocytes were examined by flow 
cytometry.  These results revealed a significant increase (P<0.05) in the percent of CD8+ cells 
(Figure 3.6) within the tumors of the mice receiving the high dose combination treatment in 
comparison to the PBS treatment.  There was no significant alteration in the total cellularity within 
the spleens of either of the combination groups when compared to the PBS control groups 
(Figure 3.7).  No alterations were observed in body weight, physical appearance or behavior 
(data not shown). 
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Figure 3.6.  MCNeuA Cell Xenograft Study Lymphocyte Assessment.  At the end of 
experiment, the tumors were dissected and lymphocytes were enriched from a portion of 
the tumor via density centrifugation.  The total CD8+ tumor infiltrating lymphocytes were 
assessed by flow cytometry and results, shown above as a percent of total cells in 
gradient, revealed a significant increase in the CD8+ cells in the high combination group 
(P<0.005). 
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Figure 3.7.  MCNeuA Cell Xenograft Study Splenocyte Assessment.  At the end of 
experiment, the spleens were dissected.  The splenocytes were enumerated and no 
difference was observed upon treatment with G129R-IL2 containing regimen. 
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 3.4.3 MMTV-neu Transgenic Mouse Mammary Tumor Surgical Model Studies 
Based upon the results from MCNeuA xenograft study, two different combination 
regimens were used in the surgical tumor model study.  After surgical removal of the primary 
tumor, the mice were treated with PBS, G129R, three individual fusion proteins alone, or 
combination of the three G129R fusion proteins (low or high doses).  Kaplan-Meier survival 
analysis was performed using tumor recurrence as the endpoint (Figure 3.8). The overall 
significance of the study when all treatment groups were included was found at P<0.004.   
The median values for tumor recurrence were doubled in the low combination treatment 
group (34 days) and nearly tripled in the high combination treatment group (50 days) (Figure 3.8), 
each resulting in a highly significant delay P<0.02 and 0.0002 respectively.  All three individual 
fusion proteins, G129R-PE38KDEL (40 days), G129R-IL2 (31.5 days), G129R-Endostatin (39 
days) significantly (P<0.02) delayed the median values (Figure 3.9) relative to PBS.  Also, the 
high combination was significantly better at delaying tumor recurrence than any of the individual 
fusion proteins (P<0.05).  Log rank analysis of the survival data revealed a significant difference 
between the curves. 
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Figure 3.8.  Kaplan-Meier Survival Analysis of the Combination Doses for the MMTV-neu 
Transgenic Mouse Mammary Tumor Surgical Study.  Tumor recurrence was used as the 
endpoint for this analysis.  A) Median tumor recurrence for PBS controls was 17 days, G129R 18 
days, low combination 34 days, and high combination 52.5 days.  The low (P<0.02) and high 
combination (P<0.002) significantly delayed the recurrence for tumors in this model.  
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Figure 3.9:  Kaplan-Meier Survival Analysis of the Components of the High Doses for the 
MMTV-neu Transgenic Mouse Mammary Tumor Surgical Study.  Tumor recurrence was 
used as the endpoint for this analysis.  Median tumor recurrence for G129R-PE38KDEL 
was 40 days, G129R-IL2 31.5 days, and G129R-Endostatin 39 days.  Each component 
was significantly different from both PBS and the high combination (P<0.02).  The Log 
Rank analysis of the survival curve reveals a highly significant difference between the 
treated groups and the control (P<0.004).   
 95
 As illustrated in Figure 3.10, metastasis to the lungs was reduced in a manner consistent 
with a dose-dependent effect by the combination treatments, with the group receiving the high 
dose combination developing lung metastasis only 40% of the time, compared to 78% for PBS.  
This reduction was also significantly lowered by G129R-PE38KDEL (30%).  It was interesting to 
point out that although there was no difference between the G129R treatment group and the PBS 
control group in median values for tumor recurrence (18 and 17 days, respectively, Figure 3.8), 
there was a significant reduction (33%) in lung metastasis in the group receiving G129R 
treatment  as compared to PBS control.  All other individual treatments showed no significant 
reduction in lung metastasis.  A Chi-squared test for independence determined that the high 
combination, G129R, and G129R-PE38KDEL treated groups differed significantly from the PBS 
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Figure 3.10.  Total Lung Metastasis in MMTV-neu Transgenic Mouse Mammary Tumor 
Surgical Study.  Lungs were excised at sacrifice and fixed in Bouin’s fixative to observe 
metastasis.  The percentages of animals with lung metastases are reported and a Chi-
squared test for independence was utilized to determine significance.  The high 
combination, G129R and G129R-PE38KDEL were significantly reduced in comparison to 
the PBS treated group (*P<0.1, ** P<0.05).  Both the G129R-IL2 and G129R-Endostatin 
fusion alone were significantly higher then the high combination (†  P<0.05) 
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 group and that the G129R-IL2 and G129R-Endostatin receiving groups differed from the high 
combination treated group. There was no appreciable difference between the age of mice at time 
of surgery and the mass of tumors removed nor were there any signs of toxicity, i.e. no alteration 
in body weight, appearance or behavior. 
To demonstrate the effectiveness of the fusion protein, responses of specific biomarkers 
were also examined using secondary tumor samples at the end of study.  Since G129R-
Endostatin fusion protein was designed to serve as a targeted angiogenesis inhibitor, the blood 
vessel density (measured by CD31 level, an endothelial cell marker) within the recurrent tumors 
was examined.  An obvious decrease in CD31 positive structures was observed in all treatment 
groups when compared to the PBS group suggesting a reduced vessel density within the tumors 
(Figure 3.11).  However, there does not appear to be a difference between the treatment groups.  
To examine response to the G129R-IL2 fusion protein, tumor sections were stained with CD4, a 
marker of T helper cells.  There was a remarkable increase in the CD4+ cells observed in the 
treatment groups when compared to the PBS treated group (Figure 3.12). 
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Figure 3.11.  Tumor Vessel Density. Assessment for MMTV-neu Transgenic Mouse 
Mammary Tumor Surgical Study.  Representative sections of tumors from PBS Controls, 
G129R-Endostatin, and low and high combinations tumors after treatment stained with 
CD31 and identified by DAB.  Sections were counter stained with Hemotoxin.  Vessel 
Density was remarkably lowered after primary tumor removal and treatment with the fusion 
protein combinations or G129R-Endostatin alone.  Magnification, top of each pane 40x and 
bottom of each pane 200x. 
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Figure 3.12.  Tumor Infiltrating Lymphocyte Assessment for MMTV-neu Transgenic Mouse 
Mammary Tumor Surgical Study.  Representative sections of tumors from PBS Controls, 
G129R-IL2, and low and high combinations tumors after treatment stained with CD4 and 
identified by DAB.  Sections were counter stained with Hemotoxin.  The treatment 
regimens were able to increase the CD4+ cells within the tumors after primary tumor 
removal and treatment with the fusion protein combinations or G129R-Endostatin alone.  
Magnification, top of each pane 40x and bottom of each pane 200x. 
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 3.5 Discussion 
Conventional cancer treatment begins with radiation therapy or small molecules that 
target DNA synthesis and replication activities.  Treatment is usually followed by surgical removal 
of the shrunken mass, which is followed by another round of radiation and/or chemotherapy 
(Carlson, Anderson et al. 2007).  While there have been vast improvements in the equipment for 
delivering radiation therapy (Romanelli, Schaal et al. 2006) and new methods of administering the 
chemotherapy (Kim 2007), these agents often damage many other cells, thereby creating 
significant side effects.  The use of these agents in combination in order to reduce the dose 
needed and also improve the therapeutic outcome represents the current trend, but are still only 
focusing on one aspect of cancer cell physiology, DNA replication.   
Cancer chemotherapy has made a shift in the past 10 to 15 years, with a move toward 
specifically targeting cancer cells.  To achieve this goal, efforts have been aimed at focusing the 
therapeutic agents to the cancer cells themselves by exploiting overly expressed receptors, 
antigens, or the angiogenic needs of tumors.  There are several means by which these targets 
can be utilized and therapeutic agents developed.  First of which is modulation of ligand 
concentration.  Bevacizumab, a monoclonal antibody for VEGF, accomplishes this goal by 
sequestering the ligand (Muhsin, Graham et al. 2004) for the VEGFR.  Another way to elicit an 
effect on the receptor is to modulate its signaling directly.  This has been accomplished by 
conventional small molecules, like gefitinib and erlotinib, which target EGFR (Nicholson, Staka et 
al. 2004) and sunitinib which targets both VEGFR and PDGFR (Chow and Eckhardt 2007).  
Finally, the active site of the receptor can be blocked.  Monoclonal antibodies have been 
devolved to achieve this goal, such as panituzumab and cetuximab both of which target the 
extracellular domain of EGFR (Nicholson, Staka et al. 2004). 
Receptor based targeting of breast cancer has yielded a wide array of options for the 
treatment of the disease.  Estrogen concentrations can be modulated through the use of 
aromatase inhibitors (Morandi, Rouzier et al. 2004).  The estrogen receptor itself has been the 
focus of an entire class of drugs developed to treat breast cancer, SERMs, first of which was the 
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 small molecule estrogen analog Tamoxifen (Jordan 1976) which has become a viable weapon in 
the treatment of ER positive breast cancers.  The activity of HER-2 can be modulated by the 
monoclonal antibody Herceptin, specific to the extracellular domain of HER-2 (Pal and Pegram 
2007), and the small molecule tyrosine kinase inhibitor of ErbB-1 and HER-2, lapatinib (Bilancia, 
Rosati et al. 2007).  The over-expression of PRLR in breast cancer led to the development of a 
protein based antagonist, G129R, that binds to the active site without eliciting signaling 
transduction (Chen, Ramamoorthy et al. 1999) as well as fusion proteins of G129R (Zhang, Li et 
al. 2002; Beck, Chen et al. 2003; Langenheim and Chen 2005).   
Combination strategies are evolving to utilize both traditional and targeted therapies to 
fight cancer.  These methods are based on at least three distinct principles.  First of which is to 
use agents that attack the same oncogene with difference mechanisms.  This is being utilized in 
HER-2 positive breast cancer by treating with both herceptin and lapatinib (Pal and Pegram 
2007).  Cetuximab has been utilized in combination with various small molecule tyrosine kinase 
inhibitors, gefitinib or erlotinib, in mouse xenograft studies and shown significant reduction in 
proliferative markers when use in combination (Huang, Armstrong et al. 2004; Matar, Rojo et al. 
2004).    Utilizing SERMs in combination with aromatase inhibitor would also be an example of 
this strategy.  These combinations have shown that timing of administration can be an important 
factor in determining success in that it works better when administered sequentially rather then in 
direct combination (Poole and Paridaens 2007).   
The second combination strategy being employed is targeting multiple targets along the 
same oncogenic signaling cascade.  The use of a receptor targeting drug in combination with a 
drug targeted to a particular intracellular component of its signaling cascade provides an example 
of this method.  The src homology domain has been shown to have a critical effect on HER-2 
signaling and important for HER-2 over-expressing cancers to metastasize (Schade, Lam et al. 
2007); therefore, the use of dasatinib, a small molecule inhibitor of src and abl, could prove to be 
beneficial when used in combination with herceptin (Finn, Dering et al. 2007).  Prolactin has also 
been shown to activate HER-2 receptor signaling in breast cancer (Yamauchi, Yamauchi et al. 
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 2000; Huang, Armstrong et al. 2004), and the use of herceptin in combination with the PRLR 
antagonist, G129R, has shown have a additive inhibitory effect on HER-2 and MAPK 
phosphorylation, cell proliferation in T47D and BT-474 cells both in vitro and in vivo (Scotti, 
Langenheim et al. 2007).     Most of these methods have yet to make it to clinical trials, but do 
show great promise. 
Finally, targeting multiple hallmarks of cancer by combining cancer therapeutics is under 
investigation.  The vast majority of the new targeted therapies have been shown to sensitize or 
improve the efficacy of more traditional chemotherapies that are focused on DNA replication.  
Herceptin has been shown to increase the response rate with decreased cardiac events over 
paclitaxel when used in combination (Dawood, Gonzalez-Angulo et al. 2007).  Similar findings 
have been demonstrated with bevacizumab and carboplatin/paclitaxel or gemcitabine/cicplatin.  
The use of Tamoxifen and aromatase inhibitors as adjuvant therapies also falls into this strategic 
category, and both of these agents are common drugs used in the treatment of breast cancer with 
traditional chemo and radiation (Carlson, Anderson et al. 2007).  Lastly, the combination of 
cetuximab, targeting the growth factor sensitivity hallmark, with bevacizumab, targeting the 
angiogenesis hallmark, has been demonstrated effective in small cell lung caner (Thatcher 2007).  
In this study, data is presented on a combinational strategy using three multi-functional 
fusion proteins to target breast cancer and multiple hallmarks of cancer.  Each fusion contains an 
active G129R moiety which targets the protein to breast cancer cells via the PRLR.  Each fusion 
also retains the activity of the second moiety, which has been demonstrated to exploit a different 
hallmark of cancer, immune system evasion (G129R-IL2), limitless replication potential (G129R-
PE38KDEL), and the angiogenic requirements of the tumor (G129R-Endostatin).  These activities 
have all been demonstrated in vitro (Zhang, Li et al. 2002; Beck, Chen et al. 2003; Langenheim 
and Chen 2005).  The demonstration of the in vivo capabilities of the fusion proteins has been 
limited to a decrease in growth of breast cancer cell xenografts.  These results are confirmed 
(Figure 3.4 and 3.5) utilizing another epithelial breast cancer cell line derived from the MMTV-neu 
mouse tumor, MCNeuA (Campbell, Wollish et al. 2002).  This cell line relates well to the surgical 
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 model tested, as well as giving a more convenient and quicker xenograft model to optimize 
dosages.  The data presented here represents the first demonstration of the in vivo capabilities of 
the second moiety of the fusion proteins.  The T-cell infiltration in the xenograft and surgical 
models (Figures 3.6 and 3.12) demonstrate the ability of G129R-IL2 to enhance the immune 
response within the tumor.  The decrease in blood vessel within the tumors of the surgical model 
indicates (Figure 3.11) that G129R-Endostatin can limit angiogenesis in vivo. 
While the human xenograft nude mouse model has proven to be useful for drug efficacy 
screening in vivo, the surgical model presented here may better approximate the clinical setting in 
which a patient has a naturally occurring tumor surgically removed and receives adjuvant therapy.  
The xenograft model lacks the host-tumor cell interaction and in particular lacks the immune 
system influence on the tumor, which is a vital component when dealing with a fusion protein that 
modulates the immune system.  In addition, the xenograft model does not characterize the 
natural tumor developmental process, i.e., initiation and promotion.  Xenografts are comprised of 
a single cell type with limited vascualization.  Furthermore, the efficacy of drugs demonstrated in 
a xenograft model does not reflect the clinical setting, which in most cases is measured by 
inhibition of tumor recurrence and metastasis.  For these reasons, it has been argued that 
transgenic models may offer a better alternative for drug efficacy studies in cancer (Kerbel 1998; 
Rosenberg and Bortner 1998). 
Therefore, a more clinically relevant tumor model was used to test the efficacy to the 
combination.  The MMTV-neu mouse is a well-studied and characterized model for breast cancer.  
The rate of tumor formation in these mice is very predictable; 50% of female MMTV-neu mice will 
develop mammary tumors by age 205 days and a great majority will eventually develop tumors 
(Guy, Webster et al. 1992; Muller, Arteaga et al. 1996).   This model has been shown to efficiently 
mimic human HER-2 positive breast cancer, a particularly aggressive subset of breast cancer.  
To simulate a clinical setting, the primary tumors were surgically removed from the mice after 
reaching a predetermined size.  Mice were administered the designed treatment regiments and 
the ability of the drugs to prevent recurrence and metastasis was monitored.  The in vitro data 
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 (Figure 3.3), showed the refractory nature of G129R in this Neu driven tumor system.  Similarly, 
in the surgical model (Figure 3.8) daily treatment with G129R (200 µg daily five days a week) was 
not statistically different from the control group.  However, the G129R fusion proteins significantly 
delayed tumor recurrence and reduced lung metastasis, decreased the blood vessel density 
within the tumor, and increased the quantity of CD4+ cells within the recurrent tumors.  This 
demonstrated the effectiveness of G129R as a breast cancer targeting moiety and the ability of 
the second moieties to effectively retard the recurrence rate (Figure 3.9). 
  The results demonstrate a highly significant and dosage-dependent delay in tumor 
recurrence within the combination treated groups (Figure 3.8).  If the life expectancy of a human 
female (Minino, Heron et al. 2006) was compared with that of the MMTV-neu mouse (Anisimov, 
Arbeev et al. 2004), an average of 17 days post-surgery tumor-free phase in the control group 
translates to approximately 3-5 years.   Thus, the low dose combination treatment resulted in a 2-
fold increase in the tumor-free phase (34 days).  The tumor recurrence rate in the high 
combination treated group was almost triple that of the control group.  In comparison, Herceptin, 
a popular treatment for HER-2 positive breast cancers, has been shown to be effective in 
approximately 30 to 50% of HER-2 patients with average life extension of 3 years when used in 
combination with radiation, taxanes or other traditional chemotherapies (Romond, Perez et al. 
2005; Jackisch 2006).   
Recurrence of a primary tumor or development of another tumor by itself is normally not 
the leading cause of morbidity within cancer patients.  Metastasis of the tumor to a distant site is 
typically the leading cause for the deterioration of the patient and ultimately determines the 
patient’s ability to survive after surgical removal.  At both dosages used in the surgical model, the 
combination treatment reduced the risk of developing a distant metastasis by greater than 50%.  
This ability to measure distant metastasis is a furthered argument for the validity and clinical 
relevancy for the surgical model presented herein.   
The data presented here represents a multifaceted targeting of the hallmarks of cancer 
and is the first demonstration of the second moiety functionality of the fusion protein in vivo.  The 
 105
 xenograft study presented demonstrates that there is an increase in tumor infiltrating lymphocytes 
in the combination treated group, which may decrease the capability of the tumor cells to invade 
and metastasize.  In the surgical model, a decrease in blood vessel formation was shown within 
the secondary tumors, where previous work only showed the in vitro capabilities of the second 
moiety (Zhang, Li et al. 2002; Beck, Chen et al. 2003).  A highly significant increase in median 
survival is shown within this unique surgical model.  This study also demonstrates the ability of 
the combination treatments to work superior to the individual components that compose the triple 
cocktail.  In conclusion, this data presents a novel approach to specifically target multiple 
hallmarks of cancer for the treatment of breast cancer which was demonstrated to be significantly 
effective in a unique clinically relevant model.   
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 CHAPTER FOUR 
SUMMARY 
The major objective of this study was to investigate the chemopreventative and 
therapeutic benefits of the human prolactin antagonist, G129R, in vivo.  The in vitro benefits of 
G129R, such as decreased STAT signaling, increased apoptosis and decreased cell proliferation 
have been previously demonstrated (Chen, Ramamoorthy et al. 1999; Cataldo, Chen et al. 2000; 
Llovera, Pichard et al. 2000; Beck, Peirce et al. 2002; Peirce and Chen 2004).  To accomplish 
this goal, two unique in vivo systems were utilized.  First, transgenic mice expressing G129R or 
hPRL under the control of the metallothionein promoter were used as a chemopreventative 
model.  Here the transgenic mice and their non-transgenic littermates were fed a chemical 
carcinogen, DMBA.  This model showed that constant low exposure of G129R could significantly 
decrease mortality and breast cancer incidence when exposed to the carcinogen.  The phenotype 
and microarray data observed in the G129R transgenic mice support the idea that G129R inhibits 
PRL within the mammary gland, as demonstrated by the decreased alveolar bud formation and 
the decrease in expression signatures observed related to PRL signaling, proliferation and 
metabolism. 
The second system utilizes another transgenic mouse line.  In this instance, the MMTV-
neu mouse, which acquires tumors of the mammary gland at a very predictable interval, was 
used as a surgical model of breast cancer and the therapeutic benefits of G129R were assessed.  
This model simulated the clinical treatment of breast cancer in that removal of the malignant 
mass is followed by treatment to prevent metastasis and recurrence.  While there was no 
significant delay in the time until recurrent tumor formation, there were significantly fewer 
individuals in the G129R treatment group that obtained lung metastasis.  This suggests that 
G129R would increase the survival rate post surgery, had there not been a need to sacrifice the 
mice to investigate biomarkers and metastasis. 
Furthermore, this surgical model was utilized to test the feasibility of using three G129R 
based fusion proteins (Zhang, Li et al. 2002; Beck, Chen et al. 2003; Langenheim and Chen 
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 2005) in combination.  Two doses were chosen for the surgical study, based on xenograft studies 
with a cell line derived from the MMTV-neu mouse followed by the components of the high 
combination administered individually.  As mentioned above, G129R administered at a greater 
frequency and larger dosage was unable to delay recurrence in this surgical model.  However, 
two combination doses and each individual treatment were able to significantly delay tumor 
recurrence and in most cases (high and low combo, G129R, and G129R-PE38KDEL) lower the 
percentages of mice obtaining lung metastasis.  The data showing tumor infiltrating lymphocytes 
and the decreased blood vessel formation are the first demonstration of the function of the IL-2 
moiety or the Endostatin moiety on their respective G129R based fusion protein in an in vivo 
system.  
The data presented demonstrate the in vivo capabilities of G129R and G129R based 
fusion proteins as chemopreventative and chemotherapeutic agents, both individually and in 
combination.  The combination of these three fusion protein represents a novel approach to 
specifically target multiple hallmarks of cancer for the treatment of breast cancer which was 
demonstrated to be significantly effective in a unique clinically relevant model. 
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